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1. INTRODUCTION 
Oral administration of drugs has been the most common and preferred route for 
delivery of most therapeutic agents. It remains the preferred route of administration 
investigated in the discovery and development of new drug candidates and formulations. 
The popularity of oral route is attributed to patient acceptance, ease of administration, 
accurate dosing, cost effective manufacturing methods and generally improved shelf life 
of the product. In recent years, considerable attention has been focused on development 
of sustained release drug delivery systems. The rationale for the development of sustain 
release drug delivery system of a drug is to enhance its therapeutic benefits, minimizing 
its side effects while improving the management of the diseased condition.1 
An ideal drug delivery system should deliver the drug at the rate dictated by the 
needs of the body over the period of treatment i.e. it should provide the desired 
therapeutic concentration of drug in the plasma and maintain it constant for the entire 
duration of treatment. 
Sustained release (SR) dosage forms continue to draw attention in the search for 
improved compliance and decrease the incidence of adverse drug reactions2.  A sustained 
release system includes any delivery system that achieves slow release of the drug over 
an extended period of time.3 
 In recent years, in association with progress and innovation in the field of 
pharmaceutical technology, there has been an increasing effort to develop sustained 
release dosage forms for many drugs. The primary objective of this system is to ensure 
safety and to improve efficacy of the drugs as well as patient compliance. This is 
achieved by better control of plasma drug levels and less frequent dosing. 
Pharmacokinetic theory suggests that the ultimate method for reducing the plasma 
maximum concentration (Cmax) to plasma minimum concentration (Cmin) ratio is to have 
zero- order absorption. Once steady state is achieved under these conditions, drug 
concentration in plasma is constant as long as absorption persists. Successful 
commercialization of an extended release formulation is usually challenging and involves 
consideration of many factors such as physiochemical properties of the drug, 
physiological factors, and manufacturing variables.1 
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  The United States Pharmacopoeia (USP) defines the modified-release (MR) 
dosage  form as “the one for which the drug release characteristics of time course   and/or  
location are chosen to accomplish therapeutic or convenience objectives not offered by 
conventional dosage forms such as solutions, ointments, or promptly dissolving  dosage 
forms”4. One class of MR dosage form is an extended-release (ER) dosage form and is 
defined as the one that allows at least a 2-fold reduction in dosing frequency or 
significant increase in patient or therapeutic performance when compared with that 
presented as a conventional dosage form (a solution or a  prompt drug-releasing dosage 
form). The terms “controlled release (CR)”, “prolonged release”, “sustained or slow 
release (SR)” and “long-acting (LA)” have been used synonymously with “extended 
release”. The commercial branded products in this  category are often designated by 
suffixes such as CR, CD (controlled delivery), ER, LA, PD (programmed or prolonged 
delivery), Retard, SA (slow-acting), SR, TD  (timed delivery), TR (timed release), XL 
and XR (extended release).  
 
1.1. Advantages and limitations of a sustained release (SR) dosage form  
       Clinical advantages5 
 Reduction in frequency of drug administration. 
 Improved patient compliance. 
 Reduction in drug level fluctuation in blood. 
 Reduction in total drug usage when compared with conventional therapy. 
 Reduction in drug accumulation with chronic therapy. 
 Reduction in drug toxicity (local/systemic). 
 Stabilization of medical condition (because of more uniform drug levels). 
 Improvement in bioavailability of some drugs because of spatial control. 
 Economical to the health care providers and the patient. 
 
1.1.1. Commercial/industrial advantages 
 Illustration of innovative/technological leadership. 
 Product life-cycle extension. 
 Product differentiation. 
 Market expansion. 
 Patent extension. 
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   1.1.2. Potential limitations 
 Delay in onset of drug action. 
 Possibility of dose dumping in the case of a poor formulation strategy. 
 Increased potential for first pass metabolism. 
 Greater dependence on GI residence time of dosage form. 
 Possibility of less accurate dose adjustment in some cases. 
 Cost per unit dose is higher when compared with conventional doses. 
 Not all drugs are suitable for formulating into ER dosage form. 
 
 1.2. Criteria for the selection of drug for sustained release dosage form6 : -  
             A number of drug characteristics need to be considered in evaluating drug 
molecules for sustained release dosage form. Some of these characteristics are as follows 
 
Biopharmaceutical Characteristics of the drug:  
1.2.1. Dose:  
The formulation of sustained release drug products may not be practical for drugs 
with large conventional dose (>500mg). Because, the size of the SR drug product would 
have to be quite large for the patient to swallow easily. 
 
1.2.2. Aqueous solubility:   
The rate of dissolution is directly proportional to aqueous solubility. Therefore the 
aqueous solubility of a drug is the limiting factor in its dissolution. In general, too high or 
too less aqueous solubility of a drug is undesirable for formulation of sustained release 
dosage form. A drug with very low solubility and slow dissolution rate will exhibit 
dissolution-limited absorption and yield inherently sustained blood level. High solubility 
drugs release at faster rates because of their diffusion driving force would be highest are 
also great challenge for sustain release dosage form.                                                                 
 
1.2.3. Partition Coefficient:   
Drugs with extremely high partition coefficient readily penetrate the membranes, 
but are unable to proceed further. While drugs with excessive aqueous solubility i.e. low 
oil/water partition coefficient cannot penetrate the membrane well. Therefore an ideal 
drug candidate is one which has a balanced partitioning between oil and water phase. 
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1.2.4. Drug stability:  
Drugs unstable in Gastro-intestinal environment cannot be administered as oral 
sustained release formulation because of bioavailability problems. 
 
1.2.5. Mechanism and Site of absorption:  
Drugs absorbed by carrier-mediated transport process and those absorbed through 
a window are poor candidates for controlled release system e.g. several B vitamins  
 
1.2.6.  Molecular size and Diffusivity:  
The lower the molecular weight, the faster and more complete the absorption. In 
addition to biological membrane the molecule has to diffuse through a polymeric matrix 
in most of sustained release dosage forms.  This diffusion is function of diffusivity of the 
drug. Diffusivity is defined as the ability of drug to diffuse through the membranes and it 
is inversely proportional to molecular size.  
 
1.3. Pharmacokinetic Characteristics of the drug:  
1.3. 1. Absorption:  
For a drug to be administered as controlled release formulation, its absorption rate 
(Ka) must be efficient since the desired rate – limiting step is rate of drug release Kr. i.e. 
Kr<<Ka. A drug with slow absorption is a poor candidate for such dosage forms since 
continuous release will result in a pool of unabsorbed drug.  
 
 
1.3.2. Elimination Half Life:   
Smaller the t1/2, larger the amount of drug to be incorporated in the sustained 
release dosage form. Drugs with half life in the range of 2 to 8 hours make good 
candidates for such a system. 
 
1.3.  Rate of Metabolism:                                                                                                                 
A drug, which is extensively metabolized, is suitable for controlled release system 
as long as the rate of metabolism is not too rapid. A drug capable of inducing or 
inhibiting metabolism is a poor candidate for such a product since steady-state blood 
level would be difficult to maintain. 
 
1.3.4. Dosage form index: 
 It is defined as the ratio of max steady state conc.(Css.max) to min. steady state 
conc.(Cssmin). Since the goal of sustained release formulation is to improve therapy by 
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reducing the dosage form index while maintaining the plasma drug levels within the 
therapeutic window, ideally its value should be as close to one as possible.  
 
1.4. Pharmacodynamic Characteristics of the Drug 
1.4.1 Plasma concentration-Response Relationship:-  
Drugs whose pharmacological activity is independent of its concentration are poor 
candidates for sustained release systems.    
 
1.4.2. Therapeutic index:    
The release rate of the drug with narrow therapeutic index should be such that the 
plasma concentration attended is within the therapeutically safe and effective range.   
 
1.5. Various Technologies of sustained release dosage form3:  
                  Technologies for designing of sustained release oral dosage forms can be 
classified according to two characteristics i.e. delivery mechanism and structure of the 
system. The “Delivery Mechanism” refers to physical and chemical principles involved 
i.e. dissolution, diffusion, erosion, ion exchange and osmosis. An ideal structure of a 
controlled release oral dosage form is that which allows the mechanism to yield the 
desired drug delivery rate.   
Depending upon the manner of drug release from the oral sustained release 
systems, these are classified as,  
1. Continuous release systems  
2. Delayed release system 
 
1.5.1. Continuous release systems 3 
  These systems release the drug for a prolonged period of time along the entire 
length of gastro-   intestinal tract with normal transit of the dosage form. It includes 
dissolution-controlled release, diffusion-controlled release, ion exchange, pH dependent 
and osmotic pressure controlled system. 
 
 1.5 1.1. Dissolution controlled extended-release systems3  
 A drug with a diminished dissolution rate will provide for extended release, since 
the liberation of the drug will be limited by the rate of dissolution. The following 
methods are employed to decrease the dissolution rate of active pharmaceutical 
ingredients: preparing a salt or derivative of the drug that is less soluble, coating the drug 
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with a slow dissolving material (encapsulation), or incorporating the drug into a tablet 
with a slowly dissolving carrier constituent present throughout matrix. The dissolution 
process can be considered diffusion-layer-controlled, when the rate of diffusion from a 
solid surface to the bulk solution through an unstirred liquid film is the rate-determining 
step. Once at steady state, the dissolution process is mathematically described by the 
Noyes-Whitney equation: 
 
 
Where:  
dC/dt = dissolution rate,  
A = surface area, 
KD = the dissolution rate constant (equivalent to the diffusion coefficient divided 
by the thickness of the diffusion layer D/h),                 
D = diffusion coefficient,  
Cs = saturation solubility of the solid,  
C = concentration of solute in the bulk solution 
Equation (1) predicts that the rate of release will be constant only if the physiochemical 
characteristics are held constant: surface area, diffusion layer thickness, diffusion 
coefficient, and concentration difference.  
 
1.5 1.2. Diffusion controlled systems3  
Diffusion systems are characterized by the release rate of a drug being dependent 
on its diffusion through an inert membrane barrier, which is usually a water-insoluble 
polymer. Two different types of diffusion release systems are categorized: reservoir 
devices and matrix devices.  
 
1.5 1. 3.  Reservoir Devices:                                                                                                     
Extended release formulations where film coating constitutes the main factor in 
controlled drug delivery. Examples of materials used to control drug release include 
hardened gelatin, methyl or ethyl cellulose, polyhydroxy methacrylate, methacrylate ester 
copolymers, and various waxes. Ethyl cellulose and methacrylate ester copolymers are 
the most commonly used systems in the pharmaceutical industry.  
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1.5 1. 4. Matrix extended-release systems 3 
In this system, drug in the outside layer exposed to the bathing solution first 
dissolves and then diffuses out of the matrix. The process continues with the interface 
between the bulk solution and the undissolved drug moving toward the interior. In order 
for the system to be diffusion controlled, the rate of dissolution of drug particles within 
the matrix must be much faster than the diffusion rate of dissolved drug leaving the 
matrix. Release from a monolithic matrix system can be graphically depicted as in fig. 1 
Fig.1: Graphic representation of matrix, extended-release system 
 
The release behavior for the system depicted in figure 1 can be mathematically 
described by the following equation: 
                              
 
Where, 
dM = Change in the amount of drug released per unit area 
dh = Change in the thickness of the zone of drug-depleted matrix 
C0 = Total amount of drug in a unit volume of matrix 
Cs = Saturated concentration of the drug within the matrix 
Drug release from a porous matrix involves the simultaneous penetration of bulk 
solution into the matrix resulting in the dissolution of drug and exit of the dissolved drug 
through tortuous interstitial channels and into the bulk solution.  
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1.5 1. 5. Anomalous release (diffusion and erosion) 
In certain systems there is bimodal or anomalous release of the active 
Pharmaceutical ingredient. In these systems there is diffusion as described previously. 
Additionally, the extended-release polymer may become hydrated and begin to dissolve 
leading to release upon erosion. These systems are complex and difficult to 
mathematically model since the diffusion path length undergoes changes due to polymer 
dissolution. A series of transport phenomena are involved in the release of a drug from a 
swellable, diffusion/erodible matrix2. Initially, there are steep water concentration 
gradients at the polymer/water interface, resulting in water imbibition into the matrix.6 
Due to the imbibition of water, the polymer swells, resulting in dramatic change of drug 
and polymer concentrations, increasing the dimensions of the system and increasing 
macromolecular mobility8. Upon contact with water the drug dissolves and diffuses out of 
the device. With increasing water content, the diffusion coefficient of the drug increases 
substantially3. Finally, the polymer itself dissolves.  
These systems are described in terms of fronts. The following fronts have been 
defined, with regard to anomalous release systems: the swelling front, the erosion front, 
and the diffusion front (Figure 3). The swelling front separates the rubbery region 
(swelling polymer area) which has enough water absorbed within the polymer to lower 
the glass transition temperature (Tg) of the polymer below the respective environmental 
temperature allowing for macromolecular mobility and swelling, from the non-swelling 
polymer region (where the polymer exhibits a Tg that is above the respective 
environmental temperature). The erosion front separates the matrix from the bulk solution 
and is the interface between the unstirred layer with polymer-concentration-gradient and 
the well stirred medium9 .                                            
The diffusion front is between the swelling and erosion front and separates the 
area of non-dissolved drug from the area of dissolved drug.  
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Fig. 2: Fronts in an anomalous release system 
 
 
In 1985, Peppas introduced a semi-empirical equation describing the drug release 
behavior from anomalous-release (hydrophilic) matrix systems:  
 
Where, 
Q = Fraction of drug release in time (t) 
t    = Time 
       k   = Rate constant (incorporates characteristics of polymer system and drug) 
n   = Diffusional exponent. 
The n value indicates the mechanism of drug release for each particular polymer 
drug system. For n=0.5, drug release follows a Fickian diffusion mechanism. For n=1, 
drug release occurs via the relaxation transport that is associated with stresses and phase 
transition in hydrated polymers. For 0.5<n<1, anomalous release is observed as a result 
of the contributions from both diffusion and polymer erosion10. Perhaps the most 
comprehensive modeling of a combined diffusion and erosion extended-release system 
was proposed by Siepmann and Peppas. This model accounts for water and drug 
concentration-dependent diffusion, in both the radial and axial direction of an extended-
release device, and also, accounts for three-dimensional matrix swelling, with subsequent 
changes in volume, concentration, matrix compositional changes, and  simultaneous 
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polymer dissolution. The model also accounts for drug solubility and non-homogenous 
swelling through the extended release device. 
Other extended/ sustained release systems include: 
 
 1.5 1.6.  Osmotically controlled systems: 
These are reservoir systems into which osmotically active agents are incorporated. 
The dosage form is coated with a semi permeable membrane. The orifice is made in the 
membrane layer, often with a laser. Bulk solution diffuses through the membrane and 
dissolves the osmotic agent(s) creating a high osmotic pressure within the reservoir which 
will push drug solution out of the orifice. In this type of device, drug release follows zero 
order kinetics and is pH independent.  
 
1.5 1.7. Ion-exchange systems: 
  Ion exchange resins are water insoluble, cross-linked polymers that have 
appended ionic groups along the polymer chain. Drugs are bound to these resins and 
release depends on the ionic environment and electrolyte concentration of the dissolution 
medium, as well as on the respective properties of a given ion-exchange resin. Drug is 
released through an exchange process with an appropriately charged molecule from the 
dissolution medium exchanging location with the appended drug, followed by diffusion 
of the drug out of the resin and into the bulk medium.  
 
1.5.2. Delayed release systems: 
 The design of such system involves release of drug only at a specific site in the 
gastro intestinal tract. The two types of delayed release systems are intestinal release 
system and colonic release systems.  
 
1.5.2.1. Intestinal release system:   
 A drug can be enteric coated for intestinal release for several reasons such as to 
prevent gastric irritation, prevent destabilization in gastric pH. 
 
1.5.2.2. Colonic release system: 
 Drugs are poorly absorbed through colon but are delivered to such a site for local 
action as in the treatment of ulcerative colitis or inflammatory bowel diseases. 
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1.6. Matrix systems 5 
A matrix tablet is the simplest and the most cost-effective method to fabricate an 
sustained-release dosage form. The majority of commercially available matrix 
formulations are in the form of tablets and their manufacture is similar to conventional 
tablet formulations consisting of granulation, blending, compression and coating steps. In 
its simplest form, a typical ER matrix formulation consists of a drug, release retardant 
polymer (hydrophilic or hydrophobic or both), one or more excipients (as filler or 
binder), flow aid (glidant) and a lubricant.  
 
1.6.1. Advantages: 
       It is by far the most commonly used Oral CR technology and the popularity of matrix      
systems can be attributed to several factors.  
 Unlike reservoir and osmotic systems, products based on matrix design can   be 
manufactured using conventional processing and equipment.  
 Development time and cost associated with a matrix system generally are viewed 
as favorable, and no additional capital investment is required.  
 Matrix technologies have often proven popular among the oral controlled drug 
delivery technologies because of their simplicity, ease in manufacturing, high 
level reproducibility, stability of the raw materials and dosage form, and ease of 
scale-up and process validation.  
 In recent years, considerable attention has been focused on hydrophilic polymers 
in the design of oral controlled drug delivery systems because of their flexibility 
to obtain a desirable drug release profile, cost-effectiveness, and broad regulatory 
acceptance. 
 A matrix system is capable of accommodating both low and high drug load and 
active ingredients with a wide range of physical and chemical properties. 
 
   1.6.2. Limitations: 
     As with any technology, matrix systems come with certain limitations. 
 Matrix systems lack flexibility in adjusting to constantly changing dosage levels, 
as required by clinical study outcome. When new dosage strength is deemed 
necessary, more often than not a new formulation and thus additional resources 
are expected. 
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 Furthermore, for some products that require unique release profiles (e.g., dual 
release or delayed plus extended release), more complex matrix-based 
technologies such as layered tablets (e.g., Allegra D) will be required. 
Nevertheless, we expect continued popularity of matrix systems because they 
have demonstrated success across a wide range of product profiles.  
 
 1.6.3. Types of matrix system11:  
 1.6.3.1. Solid matrix (no disintegration, no swelling) 
  For the first matrix system, only the drug at the surface is released. The release 
profile, often expressed as the amount released versus time, is a function of the change of 
surface geometry and surface area of the matrix. Therefore, the surface geometry and 
surface area play a significant role in dissolution. In addition, where water-soluble 
polymers such as polyethylene glycols are used, the viscosity in the diffusion layer 
adjacent to the dissolution surface also can contribute to the release profile and release 
rate. If the dissolution/erosion surface and the viscosity in the diffusion layer can be 
maintained constant during dissolution, a zero-order release profile is obtained. Unless 
the drug loading is very high (>50 percent), the dissolution rate of the matrix often is 
determined by the properties of excipients, mainly the solubility and viscosity. The more 
soluble the excipients and the less viscosity generated in the diffusion layer, the faster is 
the matrix dissolution. Since only dissolved drug molecules can be absorbed by the body, 
one should understand the fate of drug solid particles after they are released from the 
erosion surface of a delivery system. The drug solid particles will start to dissolve in the 
dissolution medium once they are released. 
The dissolution rate of the drug particles is a function of the solubility of the drug 
and their particle size. For drugs with solubilities 10mg/ml or higher, the dissolution rate 
of drug particles is usually much faster than the dissolution/erosion rate of matrix 
systems. Therefore, the release rate of dissolved drug molecules is almost the same as the 
erosion rate of the matrix. On the other hand, for drugs with solubilities of 0.1 mg/ml or 
less, the dissolution rate of drug solid particles can be very slow (unless the particles are 
micronized with particle size less than 10 µm) and is the rate-determining step. 
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1.6 3.2. Porous matrix (insoluble, no disintegration, no swelling) 
For the second type of matrix system, water penetrates the matrix and dissolves 
the drug particles. This is the only system where use of a polymer is not essential to 
provide controlled drug release, although insoluble polymers have been used. As the term 
suggests, the primary rate-controlling components of a hydrophobic matrix are water 
insoluble in nature. These ingredients include waxes, glycerides,fatty acids, and 
polymeric materials such as ethyl cellulose and methacrylate copolymers. To modulate 
drug release, it may be necessary to incorporate soluble ingredients such as lactose into 
the formulation. The presence of insoluble ingredients in the formulations helps to 
maintain the physical dimension of a hydrophobic matrix during drug release. As such, 
diffusion of the active form from the system is the release mechanism, and the 
corresponding release characteristic can be described by the Higuchi equation. 
Very often, pores form within a hydrophobic matrix as a result of the release of 
the active ingredient. For a porous monolithic system,  
------------------------- [4] 
Where t is the tortuosity of the matrix.Tortuosity is introduced to account for an 
increase in diffusion path length owing to branching and bending of the pores. The square 
root of time release profile is expected with a porous monolith, whereas the release from 
such system is proportional to drug loading. In addition, hydrophobic matrix systems 
generally are not suitable for insoluble drugs because the concentration gradient is too 
low to render adequate drug release. As such, depending on actual ingredients properties 
or formulation design, incomplete drug release within the gastrointestinal (GI) transit 
time is a potential risk and needs to be delineated during development [6]. With the 
growing need for optimization of therapy, matrix systems providing programmable rates 
of delivery become more important7. 
In this case, both dissolution and diffusion contribute to the release profile according to 
Eq. (5) 
--------------------- [5] 
Where, C = concentration of dissolved drug inside the matrix  
             Cs = solubility of the drug inside the matrix  
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             D = diffusivity inside the matrix  
             K = dissolution parameter of the active drug inside the matrix 
The first term on the right-hand side of the equation represents diffusion inside a 
matrix, and the second term corresponds to the particle dissolution. The dissolved drug 
molecules diffuse out of the matrix and are released into the dissolution medium. At 
pseudo-steady state (i.e., dC/dt ≈ 0), the drug concentration inside the matrix will be 
relatively constant or change slowly with time. This pseudo-steady state concentration 
inside the matrix will depend on the balance of the dissolution rate of particles and the 
diffusion rate of dissolved drug substance. If the dissolution rate is much faster than the 
diffusion rate, the pseudo-steady state concentration inside the matrix will be close to the 
solubility of the compound. This situation often happens if the solid particles are small or 
drug loading is high. On the other hand, if solid particles are large and drug loading is 
low, the pseudo-steady state concentration inside the matrix will be lower than the 
solubility of the drug substance. Chandrasekaran and Paul have found that for such 
systems where dissolution is the rate-limiting step, the release is linear with time, and the 
release rate is a zero order, as shown by 
------------------------ [6] 
where Mt and M∞ = amounts of drug released at time t and infinity 
           C0 = drug loading 
           Cs = solubility 
           D = diffusion constant of drug molecules in the matrix 
           K = dissolution constant (a function of A/V) 
           l = thickness of the slab matrix 
On the other hand, for systems where diffusion is the rate-limiting step, the release is a 
function of the square root of time, as indicated by the Higuchi equation.  
---------------------- [7] 
At the later stage of drug release, the system is always dissolution controlled 
because of the low drug loading encountered. Higuchi developed a model to describe the 
release profile of drug solids dispersed in a matrix. This model ignores the dissolution of 
drug particles inside a matrix and assumes that the concentration of a drug inside the 
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matrix is the solubility of the compound. This assumption is only true if a delivery system 
has high drug loading and is at the early stage of release, where the release is purely 
diffusion controlled. 
Another study also suggested that in dissolution controlled systems (i.e. systems 
with low drug loading, large drug particle size and at the later stage of dissolution), the 
drug release from mono dispersed spherical micro particles is a linear function of time, or 
the release rate is zero order.  
 
1.6.3.3. Water-soluble hydrophilic swellable matrix 
The third matrix system is based on hydrophilic polymers that are soluble in 
water. These are drug delivery systems in which therapeutic agent is dispersed in a 
compressed matrix made of water swellable polymers which when exposed to aqueous 
medium , the surface of polymer hydrates to form a viscous gel layer. 
The primary rate-controlling ingredients of a hydrophilic matrix are polymers that 
would swell on contact with the aqueous solution and form a gel layer on the surface of 
the system. Robust swelling/gelling properties and straightforward manufacturing 
processes are to a large degree responsible for the versatility and performance of the 
system. Hydroxypropyl methylcellulose (HPMC) is the most commonly used hydrophilic 
polymer.  
 
1.7. Dissolution of matrix systems11:  
The delivery from these systems often follows a certain time course determined 
by the selection of the polymer and the geometry of the matrix. This type of delivery 
systems is suitable for reducing the frequency of drug administration, reducing toxicity 
for drugs with a small therapeutic window, and correcting poor pharmacokinetic behavior 
such as a short half-life. When solid drug particles are embedded in matrix systems, the 
release mechanism is more complicated than that of solid-powder systems and largely 
depends on the design of the matrix systems. There are many types of matrix systems 
where the release can be expressed using different mathematical models. In this section, 
only three systems in which dissolution plays a significant role will be discussed. 
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1.7.1. Surface erodible matrix systems11  
The first system is a solid matrix that does not disintegrate nor swell during 
dissolution but dissolves from the surface that is exposed to a dissolution medium. In this 
case, the drug is released from the eroding surface, and the dissolution profile simply 
follows Eq. (8) by the Noyes and Whitney equation,  
Written as, 
 
   ----------------- [8] 
Where, 
M = mass 
t = time 
           A = dissolving surface area 
           D = diffusion coefficient 
           h = thickness of diffusion layer 
           Cs = solubility 
           Cb = concentration in bulk solution 
 
1.7.2. Non erodible systems11  
In the second matrix system, the matrix does not change during dissolution 
(insoluble, no disintegration, and no swelling). Polymers that are hydrophobic or cross-
linked polymers often are used for the matrix. The drug solid is dissolved inside the 
matrix and is released by diffusing out of the matrix. Both dissolution and diffusion 
contribute to the release profile of this type of matrix systems. The mathematical 
expression for this system can be derived from the following equation: 
 ------------------------------ [9] 
 
Where,  
C = concentration of dissolved drug inside the matrix 
            Cs = solubility of the drug inside the matrix 
            D = diffusivity inside the matrix 
            K = dissolution parameter of the active drug inside the matrix 
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The first term on the right-hand side of the equation represents diffusion inside a 
matrix, and the second term corresponds to the particle dissolution.  
 
1.7.3. Soluble matrix systems   
The third matrix system is based on hydrophilic polymers that are soluble in 
water. For these types of matrix systems, water-soluble hydrophilic polymers are mixed 
with drugs and other excipients and compressed into tablets. On contact with aqueous 
solutions, water will penetrate toward the inside of the matrix, converting the hydrated 
polymer from a glassy state (or crystalline phase) to a rubbery state. The hydrated layer 
will swell and form a gel, and the drug in the gel layer will dissolve and diffuse out of the 
matrix. At the same time, the polymer matrix also will dissolve by slow disentanglement 
of the polymer chains. This occurs only for un-cross-linked hydrophilic polymer 
matrices13-15. When such a system is in contact with an aqueous solution, at the early 
stage of release, the swelling of the matrix causes the erosion front to move outward and 
the swelling front inward. At the same time, the diffusion front is also receding owing to 
dissolution of the drug solid in the gel phase and diffusion of the dissolved drug out of 
the matrix. 
During the progress of dissolution, the polymer chains at the erosion front begin 
to disentangle and dissolve away into the dissolution medium. This surface erosion slows 
down the swelling (outward movement of the erosion front) and causes the erosion front 
to recede (inward movement of the erosion front) at the later stages of release. 
Their release profile and rate are based on the movements of different fronts (erosion 
front, diffusion front, and swelling front) during dissolution, as modeled by Eq. (10) 
------------------------ [10] 
where Mt and M∞ are the amounts of drug released at time t and infinity, and A 
and B are constants that are functions of the properties of the polymers, drugs, and 
solvents. The solubility, hydration time, and viscosity of the matrix polymers are the 
parameters that can be manipulated to change the constants A and B in Eq. (10) and to 
modify the release profile and rate of a matrix system. Since the properties of a drug to be 
delivered (such as solubility and drug loading) are also part of the constants A and B, 
selection of a polymer with appropriate properties for a certain desired release profile and 
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rate should be considered together with the properties of the embedded drug. Selection of 
polymers with low water solubility, high viscosity, and slow hydration times results in a 
slow moving erosion front. This makes the constant A in Eq. (10) much larger than 
constant B, leading to a slow release rate and Fickian release profile. Similarly, for highly 
water-soluble drugs and low drug loading, the diffusion front can move as fast as the 
swelling front. The thickness of the gel layer (distance between the erosion front and the 
swelling front) controls the release of a drug, and the drug release profile follows Fickian 
behavior. For systems with highly water soluble polymers that hydrate quickly and/or 
low viscosity, the erosion front moves fast, resulting in a faster drug release rate. In this 
case, the constant A, in Eq. (10) is much less than B, leading to a linear time release. This 
situation also can happen for high drug loading systems or not very soluble compounds, 
where the movement of the diffusion front of these systems may not be as fast as the 
swelling front. For these systems, the distance between the diffusion and erosion fronts 
controls drug release instead of the thickness of the whole gel layer (distance between the 
erosion and swelling fronts). Synchronization of the movement of the diffusion and 
erosion fronts leads to a zero-order drug release16,17& 18 . In this case, polymer dissolution 
is the release controlling factor. 
In summary, polymer dissolution (erosion) and diffusion of drug molecules across 
the gel layer have been identified as the rate-controlling mechanisms. Unlike a pure 
diffusion-controlled system, the dual release processes make hydrophilic matrices more 
suitable for insoluble molecules than other diffusion-controlled systems. That is, through 
formulation design, polymer erosion can be modulated to further aid release control of 
insoluble compounds12. 
 
1.8. Hydrophilic matrix system 
1.8.1. Classification of hydrophilic polymers5:  
1. Cellulosic : 
                        Methyl cellulose 
                        Hydroxy ethyl cellulose 
                        Hydroxy propyl methyl cellulose 
                        Sodium carboxy methyl cellulose etc. 
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2. Non – cellulosic : 
A. Natural gums/Polysaccharides - 
                        Guar gum 
                        Xanthan gum 
                        Karaya gum 
                        Carrageenans 
                        Locust bean gum 
                        Chitosan 
                         Konjac glucomannan etc. 
B. Others 
                         Polyethylene oxide 
 Homopolymers and copolymers of acrylic acid etc.  
1. Cellulosic5   
                 Chemically, HPMC is mixed-alkyl hydroxyalkyl cellulose ether containing 
methoxyl and hydroxypropoxyl groups. A general structure of cellulose ether polymers. 
Type and distribution of the substituent groups affect the physicochemical properties 
such as rate and extent of hydration, surface activity, biodegradation and mechanical 
plasticity of the polymer. 
 
2. Polysaccharides20  
Natural polysaccharides and their derivatives represent a group of polymers 
widely used in pharmaceutical dosage forms. Natural gums (like agar in the form of 
beads and konjac in the form of cylinders) have also been examined as matrices for the 
sustained release of drugs. When natural gums in the form of compressed tablets are 
placed in water, they are expected to absorb water from the medium and form a gel 
before they dissolve in the medium. If a drug is contained in the tablet, it is expected to 
be released through the gel layer, and sustained release may be achieved. Some natural 
polymers & their plant source are given below . 
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Table No. 1. Gums and their sources 
Natural gum Source 
Xanthan gum Xanthomonas campestris 
Guar gum Cyamposis tetragonolobus 
Carrageenan Chondrus crispus and Gigartina stellata 
Locust bean gum Ceratonia siliqua 
Scleroglucan Sclerotium rolfsii 
Gellan gum Pseudomonas clodea 
 
3. Others5:  
Polymers of acrylic acid are synthetic high molecular weight polymers that are 
cross-linked with either allyl sucrose or allyl ethers of pentaerythritol. Because these 
polymers are cross-linked, they are not water soluble but they swell on hydration and 
form a gel layer. In case of acrylic acid polymers, surface gel formation is not because of 
the entanglement of the polymer chains (as the polymers are already cross-linked) but 
because of the formation of the discrete microgels made up of many polymer particles. 
Polyethylene oxide (PEO) is also a non-ionic water-soluble resin, available in a variety of 
molecular weight grades ranging from 100,000 to 7,000,000 Daltons. They are the fastest 
hydrating water-soluble polymers amongst the hydrophilic polymers, which makes PEO 
products  
A suitable choice for applications where slower initial drug release is required.  
                  
1.8.2. Drug Release Mechanism: 
1.8.2.1 Glassy to rubbery polymer transition 
Swellable matrix drug delivery system must be differentiated from true swelling-
controlled delivery systems. True swelling-controlled systems are nonporous matrices in 
which the drug is essentially immobile when the polymer is glassy (dry), but relatively 
mobile when the polymer is wet and in the rubbery state. In pharmaceutical practice, 
swellable matrices are almost exclusively porous dosage forms prepared by compressing 
a powdered mixture of a drug and a hydrophilic polymer. In the swellable-matrix DDS, 
which is obtained by compressing discrete drug and polymer particles, drug delivery 
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could occur even without polymer transition. After a short time, the glassy–rubbery 
transition of the polymer creates a gel layer that acts as a barrier opposing water and drug 
transport. An exhaustive treatment of this phenomenon has been given elsewhere21.  
 When a matrix that contains a swellable glassy polymer comes in contact with a 
solvent or swelling agent, there is an abrupt change from the glassy to the rubbery state, 
which is associated with the swelling process. The individual chains, originally in the 
unperturbed state22, absorb water so that their end-to-end distance and radius of gyration 
expand to a new solvated state. This is because of the lowering of the transition 
temperature of the polymer (Tg), which is controlled by the characteristic concentration 
of the swelling agent and depends on temperature and thermodynamic interactions of the 
polymer–water system. A sharp distinction between the glassy and rubbery regions is 
observed and the matrix increases in volume because of swelling. On a molecular basis, 
this phenomenon can activate a convective drug transport, thus increasing the 
reproducibility of the drug release. The result is an anomalous non-Fickian transport of 
the drug, owing to the polymer chain relaxation behind the swelling position. This,   turn, 
creates osmotic stresses and convective transport effects23. 
 
1.8.2.2 The gel layer 
Swellable matrices are also termed gel-forming matrices, as their drug-delivery 
behavior is characterized by the formation of an outer gel layer on the matrix surface, 
owing to the associated polymer transition. If the polymer gels slowly, the solvent can 
penetrate deep into the glassy matrix, thus dissolving the drug and disintegrating the 
matrix. This gel layer acts as a ‘protective’ layer for the matrix and its stability is as 
essential as its rapid formation. Therefore, gel-layer thickness behavior is crucial in 
describing the release kinetics of swellable matrices. The gel strength is important in the 
matrix performance and is controlled by the concentration, viscosity and chemical 
structure of the rubbery polymer. This restricts the suitability of the hydrophilic polymers 
for preparation of swellable matrices. Polymers do not form the gel layer quickly are not 
suggested as excipients to be used alone in swellable matrices. However, sometimes they 
can be used in mixtures with HPMC or other polymers to modulate the swelling 
behaviour. During drug delivery, the gel layer is exposed to continuous changes in its 
structure and thickness23 typically, when the matrix tablet is exposed to an aqueous 
CHAPTER 1  INTRODUCTION 
Dept. of Pharmaceutics                                                   J.K.K.Nattraja College of Pharmacy 
 
22
solution or gastrointestinal fluids, the surface of the tablet is wetted and the polymer 
hydrates to form a gelly-like structure around the matrix, which is referred to as the “gel 
layer”. This process is also termed as the glassy to rubbery state transition of the (surface 
layer) polymer. This leads to relaxation and swelling of the matrix which also contributes 
to the mechanism of drug release. The core of the tablet remains essentially dry at this 
stage. In the case of a highly soluble drug, this phenomenon may lead to an initial burst 
release due to the presence of the drug on the surface of the matrix tablet. The gel layer 
(rubbery state) grows with time as more water permeates into the core of the matrix, 
thereby increasing the thickness of the gel layer and providing a diffusion barrier to drug 
release24 . Simultaneously, as the outer layer becomes fully hydrated, the polymer chains 
become completely relaxed and can no longer maintain the integrity of the gel layer, 
thereby leading to disentanglement and erosion of surface of the matrix. Water continues 
to penetrate towards the core of the tablet, through the gel layer, until it has been 
completely eroded.  Soluble drugs can be released by a combination of diffusion and 
erosion mechanisms whereas erosion is the predominant mechanism for insoluble 
drugs25. 
The gel layer is a hydrophilic barrier that controls water penetration and drug 
diffusion. It begins when the polymer becomes hydrated and swells. Here, the polymer 
chains are strongly entangled and the gel layer is highly resistant. However, moving away 
from this swelling position, the gel layer becomes progressively hydrated and, when 
sufficient water has accumulated, the chains disentangle and the polymer dissolves26,27 
An interesting analysis of the structure of the gel layer has been performed recently using 
texture-analysis studies28 This method offers the advantage of precisely detecting the 
glassy–rubbery boundary of the matrix. Other methods have been proposed for studying 
the gel-layer structure using nuclear magnetic resonance29, ultrasounds30 or optical 
techniques31,32 The concentration at which polymeric chains can be considered 
disentangled corresponds to an abrupt change in the rheological properties of the gel33 
This value was measured for HPMC polymers and it was not significantly different from 
the value obtained by fitting drug release data to a model equation that describes gel-layer 
and drug-release behaviour34. A good agreement was shown between the rheological 
behaviour of HPMC gels and their erosion rate35. This confirms that the polymer–
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polymer and polymer–solvent interactions are controlling factors for the gel network 
structure and erosion. 
 
1.8.2.3. Relevant front Description  
• The erosion front between the dissolution medium and the erosion (or 
dissolving) surface. 
• The diffusion front between the dissolved and undissolved drug in the gel (or 
swelled) phase. 
• The swelling front between the gel phase and the glassy (or semi crystalline) 
phase of the matrix. 
When such a system is in contact with an aqueous solution, at the early stage of release, 
the swelling of the matrix causes the erosion front to move outward and the swelling 
front inward. 
Fig.3. Schematic of a swelled hydrophilic polymer matrix showing different fronts 
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At the same time, the diffusion front is also receding owing to dissolution of the 
drug solid in the gel phase and diffusion of the dissolved drug out of the matrix. During 
the progress of dissolution, the polymer chains at the erosion front begin to disentangle 
and dissolve away into the dissolution medium. This surface erosion slows down the 
swelling (outward movement of the erosion front) and causes the erosion front to recede 
(inward movement of the erosion front) at the later stages of release36. 
 
1.8.2.4. Release Mechanism: 
 From the previous discussion, it is evident that swellable matrix tablets are 
activated by water, and drug release is controlled by the interaction between water, 
polymer and drug. The delivery kinetics depends on the drug gradient in the gel layer. 
Therefore, drug concentration and thickness of the gel layer governs the drug flux.Drug 
concentration in the gel depends on drug loading and solubility. Gel-layer thickness 
depends on the relative contributions of solvent penetration, chain disentanglement and 
mass (polymer and drug) transfer in the solvent. At the beginning, solvent penetration is 
more rapid than chain disentanglement, and a rapid build-up of gel layer thickness 
occurs. However, when the solvent penetrates slowly, owing to an increase in the 
diffusional distance, little change in gel thickness is obtained, because penetration and 
disentanglement rates are similar. Thus, the gel-layer thickness dynamics in swellable 
matrix tablets exhibit three distinct regimes. The thickness increases when solvent 
penetration is the fastest mechanism, and remains constant when the disentanglement and 
water penetration occur at a similar rate. Finally, the gel-layer thickness decreases when 
the entire polymer has undergone the glassy–rubbery transition36. Drug release kinetics 
are associated with these gel-layer dynamics, ranging initially from Fickian to anomalous 
(nonFickian), and subsequently from quasi-constant to constant, becoming first-order 
kinetics in the end. Matrices prepared using swellable polymers of high molecular weight 
rarely show all of the three regimes during the release time of the drug, because of a low 
chain disentanglement rate and insufficient external polymeric mass transfer. 
In conclusion, the central element of the release mechanism is the gel-layer 
formation around the matrix in response to water penetration. Phenomena that govern 
gel-layer formation, and consequently drug-release rate, are water penetration, polymer 
swelling, drug dissolution and diffusion, and matrix erosion. Drug release control is 
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obtained by drug diffusion through the gel layer, which can dissolve or erode. Recently, a 
convective contribution to drug transport in the gel layer, owing to the extension of 
polymer chains, was noted. This supports the anomalous behaviour observed in release 
kinetics37.  
Harland et al. developed a model for drug release based on mass balances of the 
drug and the solvent at the swelling front and the erosion front. The release profile was 
found to be a combination of Fickian and zero order, as shown by following equation 
------------------------[11] 
where Mt and M∞ are the amounts of drug released at time t and infinity, and A 
and B are constants that are functions of the properties of the polymers, drugs, and 
solvents. The model suggests that at the early stage of dissolution, the diffusion of 
dissolved drug molecules through the gel layer limits the dissolution, and the release 
profile is Fickian. 
At the later stage of dissolution, when the erosion front starts to recede, dissolution (or 
erosion) of the polymer matrix controls the release profile. Therefore, the drug release 
approaches zero order, especially when the movements of erosion and swelling fronts are 
synchronized. In general, the release profiles from water-soluble polymer matrix systems 
often are modeled simply as 
Mt/M∞ = ktn   ------------------------- [12] 
Where k is the kinetic constant that measures the rate of drug release, and n is the 
release exponent indicative of the release mechanism.  If diffusion dominates polymer 
erosion, the value of n would approach 0.5. This often happens at the early stage of 
release when the polymer matrix is swelling. On the other hand, for erosion-controlled 
formulations, n would approach the value of unity. Under an “anomalous” condition, the 
value of n falls in between 0.5 and 1 when both diffusion and erosion play roles. Figure 4. 
depicts release profiles under various conditions38. 
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Fig.4. Released amount Qt versus time t plots. Three characteristic drug release 
profiles from hydrophilic matrices, diffusion, erosional, and anomalous 
 
1.9. Formulation of Hydrophilic Matrices5: 
Typical formulation of a hydrophilic matrix consists of drug, polymer and 
excipients. These components can be compressed into tablets directly or after granulation 
by dry, wet or hot melt method depending on the nature of the drug, excipients and the 
preference for process in a particular pharmaceutical company. The various formulation 
and manufacturing considerations in the design of hydrophilic matrices are listed in 
following table. The development of hydrophilic matrices has largely been empirical. 
There is no universal recipe/methodology for designing an ER matrix formulation. One 
can formulate an ER matrix product with different hydrophilic and/or hydrophobic 
polymers using various manufacturing principles and processes.  
A metformin hydrochloride (HCl) extended-release tablet (Glucophage® XR,  
Bristol Myers Squibb) is a good example of a use of polymer combinations to  achieve a 
desired release profile. The formulation consists of a dual hydrophilic polymer matrix 
system where the drug is combined with an ionic release-controlling polymer (sodium 
carboxy methyl cellulose) to form an “inner” phase, which  is then incorporated as 
discrete particles into an “external” phase of a second non- ionic polymer, HPMC39,40.  
There are many other extended-release formulations of metformin HCl approved 
by US FDA41. These formulations range from simple monolithic hydrophilic matrix 
systems of a single polymer to combination of hydrophilic polymers with or without 
water-insoluble polymers (including enteric polymers) and hydrophobic matrices42,43. 
Although these formulations vary in their design and compositions, they all achieve 
similar extended-release profiles when tested in vitro and in vivo (bioequivalent). In the 
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following sections, some selected fundamental formulation parameters and 
manufacturing considerations for HPMC matrices are discussed as a general guideline 
Key Formulation Considerations: 
Table 2: Formulation & manufacturing considerations in the design of hydrophilic 
matrices for sustained release of drugs 
Material/Process Parameters for considerations 
I. Formulation components  
a. Drug Solubility & permeability, pka  , dose , 
stability, particle size 
b. Polymer Particle size, type, level 
c. Excipients 
Filler 
 
Level/type(solubility) 
d. Other excipients 
1. Lubricants 
 
2. Others 
 
Level/type(Stearates, non-stearates & fatty 
acids/oils) 
Release rate modifiers, stabilizers, 
solubilizers,  surfactants, buffering agents 
II. Manufacturing aspects 
    Manufacturing method 
 
a. Direct compression  Particle size of polymer/drug, flow aid 
b. Dry granulation Slugging/ roller compaction 
c. Wet granulation 
1. Solvents 
2. Binders 
 
3. Process 
 
Aqueous/non- aqueous 
Water-soluble/insoluble, enteric polymers, 
fatty acids/waxes 
Low shear 
High shear 
Fluidized bed/foamed granulation 
 
1.9.1. Formulation components 
a. Drug Properties 
Drug solubility and dose are the most important factors to consider in the design  
of ER matrices. In general, extended-release formulation of extreme drug solubilities 
coupled with a high dose is challenging. Drugs with very low solubility (e.g. < 0.01 
mg/mL) may dissolve slowly and have slow diffusion through the gel layer of a 
hydrophilic matrix. Therefore, the main mechanism of release would be through erosion 
of the surface of the hydrated matrix. In these cases, the control over matrix erosion to 
achieve consistent extended release throughout the GI tract is critical. For drugs with very 
high water solubility, the drug dissolves within the gel layer (even with small amounts of 
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free water) and diffuses out into the media. Therefore, it is important to control the 
factors that affect drug diffusivity (e.g. pH, gel strength and availability of free water) 
within the gel layer and parameters that ensure integrity of the gel layer after the drug has 
been dissolved and released from the gel layer. Drug solubility, therefore, is an important 
factor determining the mechanism of drug release from HPMC hydrophilic matrices, 
influencing the choice of polymer viscosity, chemistry and choice of excipients. Use of 
an appropriate viscosity grade will enable a formulation scientist to design matrices based 
on diffusion, diffusion and erosion or erosion only mechanisms. For water-soluble drugs, 
high viscosity grades of HPMC (Methocel K4M CR, K15M CR or K100M CR) tend to 
generate consistent diffusion controlled systems (n approaching, 0.45) . For drugs with 
poor water solubility, low viscosity grades HPMC (Methocel K100LV CR and E50LV) 
are recommended where erosion is the predominant release mechanism (n, 0.9). 
Depending on drug solubility, it may be necessary to blend polymers of different 
viscosities to obtain an intermediate viscosity grade of HPMC and achieve desired release 
kinetics. It should be noted that as drug diffusion is dependent on its molecular weight, 
chemistry and other excipients within the gel layer, drug release too is dependant on these 
properties [44]. 
Fig.5. Influence of drug solubility on their release profiles from a Methocel K4M CR 
hydrophilic matrix formulation consisting of 30% (w/w) polymer and 
microcrystalline cellulose as filler 
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Above figure shows the influence of drug solubility on release profiles for 
chlorpheniramine maleate, diclofenac sodium and theophylline from a Methocel K4M 
CR matrix formulation, keeping all other matrix composition and properties constant45. 
As aqueous solubility of the drug is decreased, drug release rate also decreases. 
For poorly soluble drugs, particle size of the drug has a major influence on its 
release profile46-48. A decrease in particle size of the drug causes increase in solubility 
and hence faster drug release rate. Hydrophilic matrix formulation of high-dose drugs 
(approximating ∼1.0 g) is challenging because of the overall dosage weight limitations 
versus the quantity of the polymer required to achieve desired release profiles. It has been 
reported that very large tablets that are formulated to be swallowed whole (e.g. ER and 
delayed release formulations) lead to poor patient compliance and therefore reduced 
market acceptability49. 
 
b. Polymer Considerations 
Polymer level and viscosity grade are the major drug release controlling factors in 
HPMC hydrophilic matrices. Depending on dosage size and desired release rate, the 
typical use level can vary from 20% to 50% (w/w) [50]. For drugs with high water 
solubility, there is a threshold level of polymer for achieving extended release, and 
further increase in polymer level may not decrease the drug release rate. However, for 
obtaining a robust formulation with consistent performance and  insensitivity to minor 
variations in raw materials or manufacturing processes, a  usage level of ≥  30% (w/w) 
has been recommended51,52. Particle size of the polymer is another important factor. The 
finer the particle size, the faster the rate of hydration of the polymer and hence better the 
control of drug release53. Coarser polymer particles used in a direct compression 
formulation have been reported to result in faster drug release than finer particles54. The 
coarser the particle size, the slower the hydration rate and gel layer formation. The way to 
circumvent this problem is the use of fine particle size grades of the polymer. For 
example, Methocel K Premium CR grades have more than 90% of particles below 
149µm or 100mesh. The methoxyl to hydroxypropoxyl substitution ratio of HPMC 
polymer also influences drug release which generally follows Methocel E (hypromellose 
2910) > K (hypromellose 2208).55 Matrices formulated with high viscosity grades of 
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HPMC form gel layers with higher gel strengths56, which results in slower diffusion and 
erosion rates and hence slower drug release.  
 
c. Presence of Other Excipients 
Fillers: 
Soluble (e.g. lactose), insoluble (e.g. microcrystalline cellulose, dicalcium 
phosphate) and/or partially soluble (e.g. partially pregelatinzed starch) fillers are   
generally used in hydrophilic matrices to enhance pharmacotechnical properties of tablets 
(improve compressibility, flow and mechanical strength) or to modify the drug release 
profile. The inclusion of fillers affects the dissolution performance of a matrix by a 
“dilution effect” on the polymer. The magnitude of the effect on the performance of 
matrices is dependant on the drug, the polymer level and the level of excipient itself. The 
presence of water-soluble fillers in high concentrations in the matrix leads to faster and 
greater water uptake by the matrix, resulting in weaker gel strength, higher erosion of the 
gel layer and therefore faster drug release. Insoluble but weakly swellable fillers such as 
microcrystalline cellulose remain within the gel structure and generally result in 
decreased release rate57. The presence of partially pregelatinzed starch such as Starch 
1500® in HPMC matrices has been reported to decrease the drug release rate. For a 
highly soluble or sparingly soluble drug, the rank order of release rate was as follows: 
lactose > microcrystalline cellulose > partially pregelatinzed starch58. 
 
d. Others 
d.1. Release rate modifiers and stabilizers:  
As discussed previously, HPMC is a non-ionic polymer and hence the polymer 
hydration and gel formation of its matrix is essentially independent of pH of a typical 
dissolution media used. However, when drugs with pH-dependent aqueous solubility 
(weak acids or bases) are formulated in HPMC matrices, they may exhibit pH-dependent 
drug release. Formulating ER matrices of such drugs may  lead to lower drug release due 
to exposure of the dosage form to increasing pH  media of the GI tract (from pH 1.2 to 
7)57. Formulating pH-independent ER matrices for such drugs would not only ensure 
adequate release throughout the physiological pH, but also lower intra- and inter-patient 
variability59,60.  
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Development of such pH-independent matrices for weakly basic drugs has been 
shown with the incorporation of acidic excipients (weak acids or salts of strong acids) 
that lower the micro-environmental pH within the gel layer and thus maintain high local 
solubility of the drug independent of the external release media61-67.  
Two types of acidic excipients have been used. The first category is “small 
molecules” or non-polymeric pH modifiers such as adipic, citric, malic, succinic, tartaric, 
ascorbic or fumaric acid and salts of strong acids such as l-cysteine hydrochloride and 
glycine hydrochloride. The second category is “large molecules” or polymeric pH 
modifiers such as sodium alginate, Carbopol and enteric polymers. The extent of micro-
environmental control of pH is dependent on the ionization constant and solubility of the 
release modifier. In general, the higher the pka of the acid, the higher the micro-
environmental pH. In addition to control of the micro-environmental pH, the polymeric 
pH modifiers may also alter the gel strength and erosion rate of the matrix and therefore 
the release rate of the drug61,65.  
The combination of these two opposing effects could also contribute to pH-
independent release profiles. Similar to basic drugs development of pH-independent ER 
matrices for weakly acidic drugs is possible with incorporation of non-polymeric 
bases/salts of strong bases and polymeric pH modifiers68,71. The examples of basic 
excipients are sodium, potassium or magnesium salts of bicarbonate, phosphate or 
hydroxide, magnesium oxide, 2-amino-2-methyl-1, 3-propanediol (AMPD) and 
Eudragit® E100.The effectiveness of this approach often depends on the properties of the 
drug and the release-modifying agent as well as the ratio of the drug to release-modifying 
excipient. In matrix systems, a small molecule pH modifier (such as tartaric acid or citric 
acid) that is water soluble can leach out of viscous gel layer fairly quickly, resulting in a 
limited change of pH in the gel layer over an extended duration of the drug release. Thus, 
it is important to design a system that retains the release modifying agent in a delivery 
device suitable for the extended period of release. Polymeric pH modifiers are a better 
choice in such situations as they have higher molecular weights and provide longer 
residence times in the matrix. However, the magnitude of pH modulation provided by the 
polymeric pH modifiers is not expected to be comparable to that provided by non-
polymeric acids, and in some cases it might be necessary to include an additional “small 
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molecule” pH modifier in the matrix formulation. pH modifiers are also used for 
improving the stability of active pharmaceutical ingredients in the matrix composition. 
Bupropion hydrochloride, for example, is an antidepressant drug that undergoes 
degradation in an alkaline environment. To formulate an acceptable ER solid dosage 
form, the use of weak acids or salts of strong acids as stabilizers in the formulation 
(tartaric acid, citric acid, ascorbic acid, l-cysteine hydrochloride and glycine 
hydrochloride) has been suggested in the literature. These stabilizers provide an acidic 
environment surrounding the active drug that prevents its decomposition72. 
 
d.2. Effect of Salts and Electrolytes : 
In general, as the concentration of ions in a polymer solution increases, polymer 
hydration or solubility decreases73. The amount of water available to hydrate the polymer 
is reduced because more water molecules are required to keep the ions in solution. 
Moreover, the types of ions in solution affect polymer hydration to varying degrees. The 
susceptibility of cellulose ethers to ionic effects follows the lyotropic series of the ions 
(chloride < tartarate < phosphates and potassium < sodium)74. Changes in the hydration 
state of a polymer in solution are manifested primarily by changes in solution viscosity 
and turbidity or cloud point. At low ionic  strengths, the polymer hydration is unaffected, 
but higher ionic strengths may lead  to a loss of gel integrity of the matrix. The extent of 
this influence depends on the  polymer type and lyotropic series of the ions. The effect of 
electrolytes or salts is  important only in cases where high concentrations of salts or 
electrolytes are  present as tablet components or as constituents of dissolution media. In-
vivo conditions, however, have fairly low ionic strength (ionic strength of gastrointestinal 
fluids, µ = 0.01–0.15) to affect the polymer hydration and have significant impact on 
release rate75. 
 
1.9.2 Method of Manufacture 
Hydrophilic matrix tablets are manufactured using traditional tablet 
manufacturing methods of direct compression (DC), wet granulation or dry granulation 
(roller compaction or slugging) depending on formulation properties or on 
manufacturer’s preference. HPMC polymers generally have very good compressibility 
and results in tablets with high mechanical strength76. It has been reported that high 
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molecular weight grades of HPMC may undergo less plastic flow than the low molecular 
weight grades and thus require higher pressures to deform77. In a matrix formulation, the 
inclusion of DC excipients and other ingredients may render the formulation for direct 
compressionwith acceptable mechanical properties of the tablets. 
Aqueous wet granulation is generally achieved using a spray system to avoid 
formation of a lumpy mass78. Addition of a binder may not be necessary as HPMC itself 
has excellent binder properties when hydrated. Over-granulation or high concentration of 
a binder beyond the optimal level could adversely affect the compressibility of the 
granules. To reduce the formation of a lumpy mass during granulation and improve 
process efficiency, a novel foam granulation technology has recently been introduced79. 
In this method, using a simple foam apparatus, air is incorporated into a solution of 
conventional water-soluble polymeric binder such as a low viscosity grade HPMC to 
generate foam. Application of such foam for granulation results in an increased surface 
area and volume of polymeric binder and therefore improves the distribution of 
water/binder system throughout the powder bed. The effect of compression force on drug 
release from hydrophilic matrices is minimal when tablets are made with sufficient 
strength and optimum levels of polymers are used80. One could relate variation in 
compression forces to a change in the porosity of the tablets. However, as the porosity of 
the hydrated matrix is independent of the initial porosity, the compression force is 
expected to have little influence on drug release rate81. Once sufficient tablet hardness 
suitable for processing and handling is achieved, tablet hardness would have little further 
effect on drug release profile. To ensure consistent porosity and avoid entrapment of air 
within the dry tablet core, a pre-compression step may have to be considered in the 
manufacture of matrices. Compression speed has been reported to adversely affect the 
tensile strength of the tablets and lower compression speed has been suggested for 
obtaining a product with better mechanical quality82-84. A robust formulation, which is 
insensitive to changes in the manufacturing processes such as over-granulation effect or 
variable tablet hardness, may be obtained by reducing the amount of intragranular HPMC 
and replacing it as an extra granular component85. 
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1.9.3. Viscous Synergism between polymers 
It is known than the blending of certain types of gums can produce a disperse 
system with a greater viscosity than the sum of the viscosities of the individual gum 
dispersions considered separately. This phenomenon is called viscous synergism86. In this 
sense, viscous synergism has been investigated between guar gum, locust bean gum, 
xanthan gum, carrageenans (k & λ)etc., and starch or other hydrocolloids based on the 
comparison of the corresponding flow curves87-91. In turn, analyses of the rheological 
properties of these preparations have contributed to further knowledge of the interaction 
between carrageenans and galactomannans92-96. Viscous synergism index,” I, defined as: 
----------------------- [13] 
where i and j represent the two gums forming the mixed system, i+j. The aqueous 
dispersions of the systems i, j and i+j must be formulated at the same total concentration. 
It is clear that the index defined by Equation (13) always presents positive values. 
However, in the study of synergism, different intervals can be considered. If I is between 
0 and 0.5, the viscosity of the mixed system will be less than the sum of the viscosities of 
its two constituent simple systems, and also less than at least one of them—thus showing 
inter-action between the two gums to be antagonistic. If Equation (13) was used in 
application to a single system itself, or to two systems of equal viscosity in the absence of 
interactions between them, then, ni = nj = ni + j and thus the synergism index would be Iv = 
0.5(i.e., indicating the lack of interaction). On the other hand, for an Iv value of between 
0.5 and 1.0, where in addition the two conditions, ni + j > ni and ni + j > nj apply, synergistic 
effects will occur. However, if either of the above two conditions are not met, the effect 
of mixing both gums lacks practical interest in terms of viscous synergism, since one of 
the two simple systems would in itself prove more viscous than the mixed system. Lastly, 
when Iv > 1, the viscosity of the mixed system, would be greater than the sum of the 
viscosities of the two simple systems, i.e. synergism would result90. 
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2. LITERATURE REVIEW 
1. Andreopoulos  et al., 2001 studied the use of xanthan gum as a carrier for controlled 
drug delivery. They prepared systems based on xanthan gum matrix containing 1%, 
2% and 5% salicylic acid was prepared and studied as controlled release devices & 
found that swelling behaviour of xanthan gum is useful in predicting the drug release 
from matrix.97 
2. Sankalia et al.,2008 studied the effect of polymeric blends of ethyl cellulose, 
microcrystalline cellulose, hydroxypropylmethylcellulose, xanthan gum, guar gum , 
Starch 1500, and lactose on in vitro release profiles were studied and fitted to various 
release kinetics models and examine a level A   in vitro – in vivo correlation ( IVIVC) 
for glipizide hydrophilic sustained release matrices. They found that direct 
compression of drug release retardant xanthan gum with other rate controlling 
excipients effectively controls glipizide release throughout the course of 12 h98. 
3. Varshosaz et a.l,2006 developed matrix sustained release tablets of highly water-
soluble tramadol HCl using xanthan gum and guar gum and compared with the 
extensively investigated hydrophilic matrices i.e. hydroxypropylmethylcellulose, 
carboxymethylcellulose with respect to in vitro drug release rate and hydration rate of 
the polymers. They found that xanthan gum has a higher drug retarding ability than 
guar gum & no synergistic effect was seen for mixtures of gums with HPMC.99 
4. Khullar et al., 1998 studied guar gum as a matrix former for sustained release tablets 
and examined mechanism of behaviour of guar gum in a polymer drug matrix and 
found that swelling behaviour of guar gum is useful in predicting the drug release 
from matrix100. 
5. Fassihi  et al., 2001 investigated the effect of ionic and non-ionic excipients and 
additives as modulators of swelling and erosion kinetics and verapamil HCl release 
from guar-based matrix tablets. They found that ionic, water soluble materials 
(sodium chloride, glycine) reduce initial hydration of the matrix and thus have the 
ability to limit the initial rapid diffusion of drug and to sustain near linear release over 
24 h101. 
6. Jun et al., 2005 investigated the effects of carrageenans (iota & lambda) and 
cellulose ethers (HPMC & MC) on the drug release rates of ibuprofen controlled-
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release tablet matrices prepared by direct compression. They found that both lambda 
and iota carrageenan can be used in combination with cellulose ethers for the 
formulation of controlled-release ibuprofen tablets102. 
7. Hernandez et al., 2001 studied the synergistic interactions between locust bean gum 
(LBG) and two types of carrageenans (k and λ). They found that the highest 
synergism corresponded to the lowest proportion of k and λ carrageenan.103 
8. Bonferoni et al., 1993compared λ carrageenan with sodiumcarboxymethylcellulose 
and xanthan gum. They found that it controls the initial burst release and drug release 
is independent of pH of the dissolution of the medium104.  
9. Bonferoni et al., 1994 studied the suitability of λ-carrageenan-
hydroxypropylmethylcellulose (HPMC) matrices for the controlled release of two 
basic drugs (salbutamol sulphate and chlorpheniramine maleate). They found that λ - 
carrageenan hydrophilic matrices for sustained release of soluble basic drugs and the 
addition of HPMC can reduce the impact of the medium characteristics on the 
attrition behaviour of the matrix105. 
10. Pellicer  et al., 2000 studied an empirical approach to quantify the synergistic 
interactions & their variations with shear rate and the influence of addition of third 
gum NaCMC. They found that viscosity of xanthan gum and locust bean gum was 
three fold greater than that of xanthan gum, locust bean gum and NaCMC106. 
11. Pricl  et al., 1997 studied the synergistic gelation of xanthan gum with locust bean 
gum. They found that the highest synergistic effect is attained for the locust bean gum 
and xanthan gum 1:1 system107. 
12. Venkataraju et al., 2007 developed a controlled drug delivery of highly water 
soluble drug, propranolol hydrochloride using synergistic activity of locust bean gum 
and xanthan gum. They found that the XLBG matrices offer more precise results than 
X and LBG matrices due to the effect of a synergistic interaction between the two 
biopolymers108. 
13. Parakh et al., 2003 studied the novel method to study the water absorption rate for 
swellable matrices and predicting the role of water absorption rate in drug release 
pattern. They found that rate of water absorption depends on the ratio of polymer: 
hydrophilic excipient and polymer viscosity109.  
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14. Kinget et al., 1994 studied the swelling and drug release behaviour of xanthan gum 
matrix tablets using three drugs having different properties, i.e., caffeine as a soluble 
neutral drug, indomethacin as an insoluble acidic drug, and the sodium salt of 
indomethacin as a soluble acidic drug. They established the dependence of drug 
release on the swelling of the polymer matrix and on the type of the drugs110. 
15. Munday et al., 2000 studied xanthan gum and Karaya gum as release controlling 
agent. They found that both xanthan and karaya gums produced near zero order drug 
release with the erosion mechanism playing a dominant role111. 
16. Munday et al., 1997 studied the swelling, erosion and solvent front penetration 
properties of mini-matrices containing xanthan (X), locust bean (LB) and karaya (K) 
gums were examined, analysed and related to the overall in vitro release kinetics of 
diclofenac sodium. They found that the dominant mechanism fickian drug diffusion 
and polymer erosion depended on the nature and content of the gum, as well as the 
stage in the dissolution time period112. 
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3. AIM AND OBJECTIVES 
AIM : 
Recently, sustained release drug delivery system has become the standards in the 
modern pharmaceutical design and intensive search has been undertaken in achieving 
much better drug product effectiveness, reliability and safety. Oral sustain release 
medication will continue to account for the largest share of drug delivery systems, due to 
ease of its formulation as compared to other systems.  The biggest ascent of these type of 
systems is the ease with which they can be prepared on the large scale, and hence, easy 
commercialization. 
For treating diabetes, it has been considered important that both a post prandial 
blood glucose level and a fasting blood glucose level are decreased to make them to 
normal levels. Other antidiabetics are primarily used for decreasing either a post prandial 
blood glucose level or a fasting blood glucose level to make it close to a normal level, but 
nateglinide has been used to control both post prandial blood glucose level as well as a 
fasting blood glucose level. Nateglinide is a BCS class II (Insoluble, highly permeable) 
drug. The plasma half life of nateglinide is 1.5h. The usual oral dosage regimen is 60— 
180mg taken 3 times a day for nateglinide immediate release tablets. The nateglinide 
controlled or sustained release formulation would be more useful than the nateglinide 
immediate release tablets from the view point of avoidance of side effect, or of easy 
control of both PBG and FBG to enable control of both PBG and FBG for moderate and 
severe diabetes patients. Thus, there is a need to formulate oral sustained drug delivery 
system of nateglinide. 
The oral sustained release drug delivery system of nateglinide can be formulated 
using various synthetic as well as natural hydrophilic polymers. The biodegradable nature 
and easy availability of the natural polymers makes them suitable for using as a sustained 
release polymer. The natural polymers also exhibit a rheological synergism between them 
when two polymers are mixed together. By using this property of the natural polymers 
can be used to reduce the total polymer concentration from the sustained release matrix 
tablet and once a day formulation of the nateglinide can be formulated containing least 
amount of polymer.  
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Nateglinide [N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine] is a 
novel mealtime glucose regulator approved for the treatment of type II diabetes mellitus. 
Nateglinide has a rapid onset and short duration of insulinotropic action that results in 
reduction of mealtime glucose rise and lowers the postabsorptive potential for 
hypoglycemia in humans and experimental animals. 
 
OBJECTIVE:  
1. To prepare and evaluate once a day sustained release matrix tablet of Nateglinide. 
2. To reduce the total polymer concentration using rheological synergism between 
two natural gums. 
3. To study the invitro performance of matrix tablet. 
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4. PLAN OF WORK 
1. Literature review 
2. Selection of suitable drug and excipients  
3. Procurement of drug and excipients 
4. Characterization of drug 
5. Preformulation studies 
6. Preliminary studies 
7. Evaluation of granules 
8. Formulation and development of hydrophilic matrix tablet 
9. Evaluation of matrix tablets 
10. In vivo performance of matrix tablet  
11. Stability studies of matrix tablet 
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5. DISEASE PROFILE (14,15) 
Diabetes mellitus, often simply referred to as diabetes, is a group of metabolic 
diseases in which a person has high blood sugar, either because the body does not 
produce enough insulin, or because cells do not respond to the insulin that is produced. 
This high blood sugar produces the classical symptoms of Polyuria(frequent urination), 
Polydipsia(increased thirst) and Polyphagia(increased hunger)(27). 
 
Fig.No.6 & 6a: Comparison of Type-I & Type-II Diabetes mellitus 
 
The three main types of diabetes mellitus (DM) 
are: 
• Type 1 DM results from the body's failure to 
produce insulin, and presently requires the 
person to inject insulin. (Also referred to as 
insulin-dependent diabetes mellitus (IDDM) 
or "juvenile" diabetes) 
• Type 2 DM results from insulin resistance, a 
condition in which cells fail to use insulin 
properly, sometimes combined with an 
absolute insulin deficiency. (Formerly 
referred to as noninsulin-dependent diabetes 
mellitus (NIDDM) or "adult-onset" diabetes) 
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• Gestational diabetes is when pregnant women, who have never had diabetes 
before, have a high blood glucose level during pregnancy. It may precede 
development of type 2 DM. 
Other forms of diabetes mellitus include congenital diabetes, which is due to 
genetic defects of insulin secretion, cystic fibrosis-related diabetes, steroid diabetes 
induced by high doses of glucocorticoids, and several forms of monogenic diabetes. 
All forms of diabetes have been treatable since insulin became available in 1921, 
and type 2 diabetes may be controlled with medications. Both types 1 and 2 are chronic 
conditions that usually cannot be cured. 
Pancreas transplants have been tried with limited success in type 1 DM; gastric 
bypass surgery has been successful in many with morbid obesity and type 2 DM. 
Gestational diabetes usually resolves after delivery.  
Diabetes without proper treatments can cause many complications. Acute 
complications include Hypoglycemia, Diabetic Ketoacidosis, or Nonketotic 
Hyperosmolar Coma.  
Serious long-term complications include Cardiovascular Disease, Chronic Renal 
Failure, and Diabetic Retinopathy (retinal damage).  
Adequate treatment of diabetes is thus important, as well as blood pressure 
control and lifestyle factors such as smoking cessation and maintaining a healthy body 
weight. 
Signs and symptoms: 
 The classical symptoms of untreated diabetes are loss of weight, 
Polyuria(frequent urination), Polydipsia(increased thirst) and Polyphagia(increased 
hunger). Symptoms may develop rapidly (weeks or months) in type 1 diabetes, while 
they usually develop much more slowly and may be subtle or absent in type 2 diabetes 
(28)
. 
Prolonged high blood glucose can cause glucose absorption in the lens of the eye, 
which leads to changes in its shape, resulting in vision changes. Blurred vision is a 
common complaint leading to a diabetes diagnosis; type 1 should always be suspected in 
cases of rapid vision change, whereas with type 2 changes are generally more gradual, 
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but should still be suspected. A number of skin rashes that can occur in diabetes are 
collectively known as Diabetic Dermadromes. 
Fig.No.7 : Overview of the most significant symptoms of diabetes. 
 
 
Diabetic emergencies:                                                                                                              
People (usually with type 1 diabetes) may also present with diabetic ketoacidosis, 
a state of metabolic dysregulation characterized by the smell of acetone, a rapid, deep 
breathing known as Kussmaul breathing, nausea, vomiting and abdominal pain, and 
altered states of consciousness. 
A rare but equally severe possibility is hyperosmolar nonketotic state, which is more 
common in type 2 diabetes and is mainly the result of dehydration. 
Complications 
All forms of diabetes increase the risk of long-term complications. These typically 
develop after many years (10–20), but may be the first symptom in those who have 
otherwise not received a diagnosis before that time. The major long-term complications 
relate to damage to blood vessels. Diabetes doubles the risk of cardiovascular disease. 
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The main "macrovascular" diseases (related to atherosclerosis of larger arteries) are 
ischemic heart disease (angina and myocardial infarction), stroke and peripheral vascular 
disease. 
Diabetes also causes "micro vascular" complications—damage to the small blood 
vessels. Diabetic retinopathy, which affects blood vessel formation in the retina of the 
eye, can lead to visual symptoms, reduced vision, and potentially blindness. Diabetic 
nephropathy, the impact of diabetes on the kidneys, can lead to scarring changes in the 
kidney tissue, loss of small or progressively larger amounts of protein in the urine, and 
eventually chronic kidney disease requiring dialysis. Diabetic neuropathy is the impact of 
diabetes on the nervous system, most commonly causing numbness, tingling and pain in 
the feet and also increasing the risk of skin damage due to altered sensation. Together 
with vascular disease in the legs, neuropathy contributes to the risk of diabetes-related 
foot problems (such as diabetic foot ulcers) that can be difficult to treat and occasionally 
require amputation. 
 
Causes: 
The cause of diabetes depends on the type. 
Type 1 diabetes is partly inherited, and then triggered by certain infections, with 
some evidence pointing at Coxsackie B4 virus. A genetic element in individual 
susceptibility to some of these triggers has been traced to particular HLAgenotypes (i.e., 
the genetic "self" identifiers relied upon by the immune system). However, even in those 
who have inherited the susceptibility, type 1 DM seems to require an environmental 
trigger (29). 
Type 2 diabetes is due primarily to lifestyle factors and genetics.  
The following is a comprehensive list of other causes of diabetes:  
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Table. No. 3: causes of diabetes 
 
• Genetic defects of β-cell function  
o Maturity onset diabetes of the 
young 
o Mitochondrial DNA mutations 
• Genetic defects in insulin processing or 
insulin action  
o Defects in proinsulin conversion 
o Insulin gene mutations 
o Insulin receptor mutations 
• Exocrine pancreatic defects  
o Chronic pancreatitis 
o Pancreatectomy 
o Pancreatic neoplasia 
o Cystic fibrosis 
o Hemochromatosis 
o Fibrocalculous pancreatopathy 
 
• Endocrinopathies 
o Growth hormone excess 
(acromegaly) 
o Cushing syndrome 
o Hyperthyroidism 
o Pheochromocytoma 
o Glucagonoma 
• Infections  
o Cytomegalovirus infection 
o Coxsackievirus B 
• Drugs  
o Glucocorticoids 
o Thyroid hormone 
o β-adrenergic agonists 
o Statins[17] 
 
Diagnosis: 
Table No. 4: Diabetes diagnostic criteria 
Condition 2 hour glucose Fasting glucose HbA1c 
 
mmol/l(mg/dl) mmol/l(mg/dl) % 
Normal <7.8 (<140) <6.1 (<110) <6.0 
Impaired fasting 
glycaemia  
<7.8 (<140) ≥ 6.1(≥110) &<7.0(<126) 6.0–6.4 
Impaired glucose 
tolerance  
≥7.8 (≥140) <7.0 (<126) 6.0–6.4 
Diabetes mellitus ≥11.1 (≥200) ≥7.0 (≥126) ≥6.5 
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Diabetes mellitus is characterized by recurrent or persistent hyperglycemia, and is 
diagnosed by demonstrating any one of the following:  
• Fasting plasma glucose level ≥ 7.0 mmol/l (126 mg/dl) 
• Plasma glucose ≥ 11.1 mmol/l (200 mg/dL) two hours after a 75 g oral glucose 
load as in a glucose tolerance test 
• Symptoms of hyperglycemia and casual plasma glucose ≥ 11.1 mmol/l 
(200 mg/dl) 
• Glycated hemoglobin (Hb A1C) ≥ 6.5% 
A positive result, in the absence of unequivocal hyperglycemia, should be 
confirmed by a repeat of any of the above methods on a different day. It is preferable to 
measure a fasting glucose level because of the ease of measurement and the considerable 
time commitment of formal glucose tolerance testing, which takes two hours to complete 
and offers no prognostic advantage over the fasting test. According to the current 
definition, two fasting glucose measurements above 126 mg/dl (7.0 mmol/l) are 
considered diagnostic for diabetes mellitus (30). 
People with fasting glucose levels from 110 to 125 mg/dl (6.1 to 6.9 mmol/l) are 
considered to have impaired fasting glucose. Patients with plasma glucose at or above 
140 mg/dL (7.8 mmol/L), but not over 200 mg/dL (11.1 mmol/L), two hours after a 75 g 
oral glucose load are considered to have impaired glucose tolerance. Of these two pre-
diabetic states, the latter in particular is a major risk factor for progression to full-blown 
diabetes mellitus, as well as cardiovascular disease. 
Glycated hemoglobin is better than fasting glucose for determining risks of 
cardiovascular disease and death from any cause. 
 
Medications 
Oral medications 
Metformin is generally recommended as a first line treatment for type 2 diabetes, 
as there is good evidence that it decreases mortality. Routine use of aspirin, however, has 
not been found to improve outcomes in uncomplicated diabetes.  
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Insulin 
Type 1 diabetes is typically treated with combinations of regular and NPH insulin, 
or synthetic insulin analogs. When insulin is used in type 2 diabetes, a long-acting 
formulation is usually added initially, while continuing oral medications.[29] Doses of 
insulin are then increased to effect.  
Epidemiology 
Globally, as of 2010, an estimated 285 million people had diabetes, with type 2 
making up about 90% of the cases. Its incidence is increasing rapidly, and by 2030, this 
number is estimated to almost double. Diabetes mellitus occurs throughout the world, but 
is more common (especially type 2) in the more developed countries. The greatest 
increase in prevalence is, however, expected to occur in Asia and Africa, where most 
patients will probably be found by 2030. The increase in incidence in developing 
countries follows the trend of urbanization and lifestyle changes, perhaps most 
importantly a "Western-style" diet. This has suggested an environmental (i.e., dietary) 
effect, but there is little understanding of the mechanism(s) at present, though there is 
much speculation, some of it most compellingly presented.  
Australia 
Indigenous populations in first world countries have a higher prevalence and 
increasing incidence of diabetes than their corresponding non-indigenous populations. In 
Australia, the age-standardized prevalence of self-reported diabetes in indigenous 
Australians is almost four times that of non indigenous Australians. Preventative 
community health programs, such as Sugar Man (diabetes education),are showing some 
success in tackling this problem. 
China 
 Almost one Chinese adult in ten has diabetes. A 2010 study estimated that 
more than 92 million Chinese adults have the disease, with another 150 million showing 
early symptoms. The incidence of the disease is increasing rapidly; a 2009 study found a 
30% increase in 7 years.  
India 
India has more diabetics than any other country in the world, according to the 
International Diabetes Foundation, although more recent data suggest that China has even 
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more. The disease affects more than 50 million Indians - 7.1% of the nation's adults - and 
kills about 1 million Indians a year. The average age on onset is 42.5 years. The high 
incidence is attributed to a combination of genetic susceptibility plus adoption of a high-
calorie, low-activity lifestyle by India's growing middle class.  
United Kingdom 
About 3.8 million people in the United Kingdom have diabetes mellitus, but the 
charity Diabetes U.K. has made predictions that that could become high as 6.2 million by 
2035/2036. Diabetes U.K. have also predicted that the National Health Service could be 
spending as much as 16.9 billion pounds on diabetes mellitus by 2035, a figure that 
means that the National Health Service could be spending as much as 17% of its budget 
on diabetes treatment by 2035.  
United States 
For at least 20 years, diabetes rates in North America have been increasing 
substantially. In 2010, nearly 26 million people have diabetes in the United States, of 
whom 7 million people remain undiagnosed. Another 57 million people are estimated to 
have prediabetes. 
The Centers for Disease Control and Prevention (CDC) has termed the change an 
epidemic. The National Diabetes Information Clearinghouse estimates diabetes costs 
$132 billion in the United States alone every year. About 5%–10% of diabetes cases in 
North America are type 1, with the rest being type 2. The fraction of type 1 in other parts 
of the world differs. Most of this difference is not currently understood. The American 
Diabetes Association (ADA) cites the 2003 assessment of the National Center for 
Chronic Disease Prevention and Health Promotion (Centers for Disease Control and 
Prevention) that one in three Americans born after 2000 will develop diabetes in their 
lifetimes. 
 According to the ADA, about 18.3% (8.6 million) of Americans age 60 and older 
have diabetes.  Diabetes mellitus prevalence increases with age, and the numbers of older 
persons with diabetes are expected to grow as the elderly population increases in number. 
The National Health and Nutrition Examination Survey (NHANES III) demonstrated, in 
the population over 65 years old, 18% to 20% have diabetes, with 40% having either 
diabetes or its precursor form of impaired glucose tolerance.  
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Treatment 
Treatment goals for type 2 diabetic patients are related to effective control of 
blood glucose, blood pressure and lipids to minimize the risk of long-term consequences 
associated with diabetes. They are suggested in clinical practice guidelines released by 
various national and international diabetes agencies. 
• Blood sugar control — the goal of treatment in type 2 diabetes is to keep blood 
sugar levels at normal or near-normal levels. Careful control of blood sugars can 
help prevent the long-term effects of poorly controlled blood sugar (diabetic 
complications of the eye, kidney, and cardiovascular system). 
• Home blood sugar testing — in people with type 2 diabetes, home blood sugar 
testing is often recommended.  
• Cardiovascular risk control — the most common long-term complication of type 
2 diabetes is cardiovascular (heart) disease, which can cause myocardial 
infarction (heart attack), angina (chest pain), stroke, and even death. The risk of 
heart disease is estimated to be at least twice that of persons without diabetes. 
Classification of Antidiabetic agent 
1. Insulin 
2. Oral antidiabetic drugs  
a) Sulfonylureas 
I. First-generation agents 
Tolbutamide , Acetohexamide, Tolazamide, Chlorpropamide 
II. Second-generation agents 
Glipizide, Glyburide, Glimepiride, Gliclazide 
b) Meglitinides 
Repaglinide, Nateglinide 
c) Biguanides 
Metformin, Phenformin, Buformin 
d) Thiazolidinediones 
Rosiglitazone, Pioglitazone, Troglitazone 
e) Alpha-glucosidase inhibitors 
 
CHAPTER-6                                                                                 DRUG PROFILE  
    
Dept. of Pharmaceutics                 50       J.K.K.Nattraja College of Pharmacy 
 
6. DRUG PROFILE (15,16,17,18.19) 
1. Category:  Ant diabetic Agent 
                                         
 
Fig.8. Structure of Nateglinide 
 
2. Molecular Formula:  C19H27NO3 
 
3. Molecular weight:  317.43 
 
4. Chemical Name: Nateglinide is N-(trans-4-Isopropylcyclohexanecarbonyl)-D-
phenylalanine. 
 
5. Description : 
Nateglinide is amorphous white powder. 
 
6. Melting Range: 133 – 1390C 
 
7. Dissociation constant:  3.1 
 
8. Solubility: It is freely soluble in methanol, ethanol, and chloroform, soluble in ether, 
sparingly soluble in acetonitrile and octanol, and practically insoluble in water. 
 
9. Pharmacokinetics of Nateglinide: 
 
9.1 Half life: 1.5 hr. 
 
9.2. Absorption 
Following oral administration immediately prior to a meal, nateglinide is rapidly 
absorbed with mean peak plasma drug concentrations (Cmax) generally occurring within 1 
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hour (Tmax) after dosing. When administered to patients with Type 2 diabetes over the 
dosage range 60 to 240 mg three times a day for one week, nateglinide demonstrated 
linear pharmacokinetics for both AUC (area under the time/plasma concentration curve) 
and Cmax. Tmax was also found to be independent of dose in this patient population. 
Absolute bioavailability is estimated to be approximately 73%. When given with or after 
meals, the extent of nateglinide absorption (AUC) remains unaffected. However, there is 
a delay in the rate of absorption characterized by a decrease in Cmax and a delay in time to 
peak plasma concentration (Tmax). Plasma profiles are characterized by multiple plasma 
concentration peaks when nateglinide is administered under fasting conditions. This 
effect is diminished when nateglinide is taken prior to a meal. 
 
9.3. Distribution 
Based on data following intravenous (IV) administration of nateglinide, the steady 
state volume of distribution of nateglinide is estimated to be approximately 10 liters in 
healthy subjects. Nateglinide is extensively bound (98%) to serum proteins, primarily 
serum albumin, and to a lesser extent 1 acid glycoprotein. The extent of serum protein 
binding is independent of drug concentration over the test range of 0.1-10 µg/mL. 
 
9.4. Metabolism 
Nateglinide is metabolized by the mixed-function oxidase system prior to 
elimination. The major routes of metabolism are hydroxylation followed by glucuronide 
conjugation. The major metabolites are less potent antidiabetic agents than nateglinide. 
The isoprene minor metabolite possesses potency similar to that of the parent compound 
nateglinide. In vitro data demonstrate that nateglinide is predominantly metabolized by 
cytochrome P450 isoenzymes CYP2C9 (70%) andCYP3A4 (30%). 
 
9.5. Excretion 
Nateglinide and its metabolites are rapidly and completely eliminated following 
oral administration. Within 6 hours after dosing, approximately 75% of the administered 
14C nateglinide was recovered in the urine. Eighty-three percent of the 14C-nateglinide 
was excreted in the urine with an additional 10% eliminated in the feces. Approximately 
16% of the 14C-nateglinide was excreted in the urine as parent compound. In all studies of 
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healthy volunteers and patients with Type 2 diabetes, nateglinide plasma concentrations 
declined rapidly with an average elimination half-life of approximately 1.5 hours. 
Consistent with this short elimination half-life, there was no apparent accumulation of 
nateglinide upon multiple dosing of up to 240 mg three times daily for 7 days. 
 
10. Mechanism of Action:  
Nateglinide is an amino-acid derivative that lowers blood glucose levels by 
stimulating insulin secretion from the pancreas. This action is dependent upon 
functioning beta-cells in the pancreatic islets. Nateglinide interacts with the ATP-
sensitive potassium (K+ATP) channel on pancreatic beta-cells. The subsequent 
depolarization of the beta cell opens the calcium channel, producing calcium influx and 
insulin secretion. The extent of insulin release is glucose dependent and diminishes at low 
glucose levels. Nateglinide is highly tissue selective with low affinity for heart and 
skeletal muscle. 
 
11. Adverse effects: 
Very rarely hypoglycemia 
 
12. Dose: 
Initial dose: 120 mg orally 3 times a day before meals 
Maintenance dose: 60 to 120 mg orally 3 times a day before meals 
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7. EXCIPIENTS PROFILE 
Carrageenan 
1. Nonproprietary Names 
USP NF: Carrageenan 
 
2. Synonyms 
Chondrus extract, E407, Gelcarin, Genu, Hygum TP-1, Irish moss extract, Marine 
Colloids, SeaSpen PF, Viscarin. 
 
3. Chemical Name 
Carrageenan, κ-Carrageenan, λ-Carrageenan 
 
4. Empirical Formula and Molecular Weight 
The USPNF 23 describes carrageenan as the hydrocolloid obtained by extraction 
with water or aqueous alkali from some members of the class Rhodophyceae (red 
seaweed). It consists chiefly of potassium, sodium, calcium, magnesium, and ammonium 
sulfate esters of galactose and 3, 6-anhydrogalactose copolymers. These hexoses are 
alternately linked at the α-1, 3 and β-1, 4 sites in the polymer. 
 
5. Structural Formula 
The carrageenans are divided into three families according to the position of 
sulfate groups and the presence or absence of anhydro galactose. 
λ-Carrageenan (lambda-carrageenan) is a non gelling polymer containing about 
35% ester sulfate by weight and no 3,6-anhydrogalactose. 
ι-Carrageenan (iota-carrageenan) is a gelling polymer containing about 32% ester 
sulfate by weight and approximately 30% of 3,6-anhydrogalactose. 
κ-Carrageenan (kappa-carrageenan) is a strongly gelling polymer which has a 
helical tertiary structure that allows gelling. It contains 25% of ester sulfate by weight 
and approximately 34% of 3, 6-anhydrogalactose. 
 
6. Functional Category 
Emulsifying agent, gel base, stabilizing agent, suspending agent, sustained release tablet 
matrix, viscosity-increasing agent. 
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7. Typical Properties 
Because of the vast differences in the material that can be referred to as 
carrageenan, it is difficult to give descriptions of typical properties  
Table No. 5: Typical properties of carrageenans 
Trade 
name 
Carrageenan  
type 
Gel 
type 
Solubility 
in water Viscosity 
Use 
concentration 
(%) 
Use examples 
Gelcarin 
GP-379 
Iota Elastic, 
medium 
strength 
Hot High, 
thixotropic 
0.3–1.0 Creams, 
suspensions 
Gelcarin 
GP-812 
Kappa Brittle, 
strong 
Hot Low 0.3–1.0 Gels 
Gelcarin 
GP-911 
Kappa Brittle, 
firm 
Hot, 
partial in 
cold 
Low 0.25–2.0 Encapsulation 
SeaSpen 
PF 
Iota Elastic, 
weak 
Cold, 
delayed 
gel 
formation 
Medium, 
thixotropic 
0.5–1.0 Creams, 
suspensions, 
lotions 
Viscarin 
GP-109 
Lambda Non-
gelling 
Partial 
cold, full 
in hot 
Medium 0.1–1.0 Creams, 
lotions 
Viscarin 
GP-209 
Lambda Non-
gelling 
Partial 
cold, full 
in hot 
High 0.1–1.0 Creams, 
lotions 
Viscarin 
GP-328 
Kappa 
/lambda 
Weak Hot Medium   
–high 
0.7–1.2 Creams, 
emulsions, 
lotions 
 
8. Description 
Carrageenan, when extracted from the appropriate seaweed source, is a yellow -   brown 
to white colored, coarse to fine powder that is odorless and tasteless. 
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9. Solubility:  
Lambda carrageenan is soluble in cold water as well as hot water while kappa and iota 
carrageenan are insoluble in cold water but their sodium salts are soluble and are soluble 
in hot water without sodium salts. 
 
10. Stability and Storage Conditions 
Carrageenan is a stable, though hygroscopic, polysaccharide and should be stored    in    a 
cool, dry place.   
                    
7.2. Locust Bean Gum 
1. Nonproprietary Names 
None adopted 
 
2. Synonyms 
Carubin, algaroba, carob bean gum, carob flour, ceratonia gum, ceratonia siliqua, 
ceratonia siliqua gum, cheshire gum, E410, gomme de caroube, Meyprofleur, St.   
John’s bread. 
 
3. Chemical Name 
Carob gum  
 
4. Empirical Formula and Molecular Weight 
Ceratonia is a naturally occurring plant material that consists chiefly of a high        
molecular weight hydrocolloidal polysaccharide, composed of D-galactose and D-
mannose units combined through glycosidic linkages, which may be described 
chemically as galactomannan. The molecular weight is approximately 310 000. 
 
5. Structural Formula 
Locust bean gum is a galactomannan similar to guar gum consisting of a (1-4)-
linked β- D-mannopyranose backbone with branch points from their 6-positions linked to 
a-D-galactose (that is, 1-6-linked a-D-galactopyranose). There are about 3.5 (2.8 – 4.9) 
mannose residues for every galactose residue.  
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6. Functional Category 
Controlled-release vehicle, stabilizing agent, suspending agent, tablet binder, 
Viscosity increasing agent. 
 
7. Description 
The highly hydrophilic LBG from the seeds of Ceratonia siliqua. 
 
8. Typical Properties 
Acidity/Alkalinity        =     pH = 5.3 (1% w/v aqueous solution) 
Viscosity (dynamic)     =     1200–2500 cP for a 1% w/v aqueous dispersion 
 
9. Solubility 
Dispersible in hot water, hydrates very slowly and incompletely in cold water & 
insoluble in ethanol 
 
10. Stability and Storage Conditions 
The bulk material should be stored in a well-closed container in a cool, dry place.        
Ceratonia loses not more than 15% of its weight on drying.      
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8. MATERIALS AND INSTRUMENTS 
8.1. Materials used   
Table.No.6 :  Materials used 
S. No. Chemical and reagents Suppliers 
1 Nateglinide Glenmark pharmaceuticals ltd. 
2 K- Carrageenan Otto kemi Pvt. ltd. 
3 λ- Carrageenan Lucid Colloids ltd. 
4 Locust bean gum Research lab – fine chem ltd. 
5 Colloidal silicon dioxide Dekkan Pharmaceuticals ltd. 
6 Magnesium stearate Loba chemie pvt. ltd. 
7 Lactose monohydrate Loba chemie pvt. ltd. 
8 Polyvinyl pyrrolidone K - 30 Loba chemie pvt. ltd. 
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8.2 Instruments used 
Table.No.7 :  Instruments used 
S. No. Instrument name SUPPLIERS/MANUFACTURERS 
1 Tablet compression machine Proton Mini Press. 
2 USP Tablet Dissolution apparatus. Lab india Analytical Instruments Pvt Ltd. Mumbai , Model-DISSO 2000. 
3 UV Visible double beam 
spectrophotometer LAB INDIA UV 3000+ 
4 Monsanto hardness tester - 
5 Roche Friability tester - 
6 Vernier Calipers - 
7 Electronic balance Wensar PGB - 300 
8 Stability Chamber ROLEX 
9 Melting point apparatus VMP D 
10 FTIR BRUKER HTS-XT 
11 Sieves Indicot (India) 
12 Tapped Density Tester Electrolab 
13 Disintegration Test Apparatus,USP ROLEX 
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9. PREFORMULATION 
 Preformulation testing is an investigation of physical and chemical properties of a 
drug substance alone and when combined with excipients. It is the first step in the 
rational development of dosage forms. 
 Preformulation studies relate to pharmaceutical and analytical investigation 
carried out in supporting formulation development efforts of the dosage forms. 
       The following preformulation studies were performed for obtained sample of drug.       
 
9.1. ORGANOLEPTIC PROPERTIES  
9.1.1. Color and nature 
 Transferred small quantity of the sample on a white piece of paper spreaded the 
powder and examined visually. 
9.2. PHYSICAL CHARACTERISTICS 
9.2.1. Flow properties  
The flow properties of powder are critical for an efficient microsphere preparing. 
If the drug is identified at pre formulation stage to be “poorly flowable” the problem can 
be solved by selecting appropriate excipients. Angle of repose is defined as the maximum 
angle possible between the surface of a pile of the powder and the horizontal plane. 
Procedure 
 A funnel was kept vertically in a stand at a specified height above a paper placed 
on a horizontal surface. The funnel bottom is closed and 10gm of sample powder is filled 
in funnel. Then funnel was open to release the powder on the paper to form a smooth 
conical heap, is found by measuring in a different directions. The height of the heap was 
measured by using scale. The values of angle of repose are calculated by using the 
following formula.  
 
 Where,  
θ = Angle of the repose 
            h = Height of the heap 
            r = Radius of the heap 
                                   
θ=  (h/r) 
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Table.No. 8:  ANGLE OF REPOSE LIMITS 
ANGLE OF REPOSE  FLOWABILITY 
<25 Excellent 
25-30 Good 
30-40 Passable 
>40 Very poor 
 
9.2.2. Bulk density 
Bulk density is the ratio of mass of powder to the bulk volume. Bulk density 
largely depends on particular shape as the particle become more spherical in shape, bulk 
density is increases. 
             Bulk density is determined by measuring the volume of a known mass of a 
powder sample that has been passed through a screen into a graduated cylinder. 
Procedure 
        Bulk density of the granules was determined by pouring gently 5gms of sample    
through a glass funnel into a 10ml graduated cylinder. The volume occupied by the 
sample was recorded. The bulk density was calculated as follows: 
 
 
9.2.3. Tapped density 
Tapped density is the ratio of mass of powder to the tapped volume. 
 
Procedure 
        5 grams of granule sample was poured gently through a glass funnel into a 10ml 
graduated cylinder. The cylinder was tapped from height of 2 inches until a constant 
volume was obtained. Volume occupied by the sample after 50 tapping were recorded 
and tapped density was calculated as follows:  
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9.3.1. Measurement of powder compressibility 
The compressibility index is measures of the propensity of a powder to be 
compressed. As such, they are measures relative importance of inter particulate 
interactions. In a free flowing powder, such interactions generally less and tapped 
densities will be closer in value. For poorer flowing materials, there are frequently greater 
inter particulate interactions, and a greater difference between bulk and tapped densities 
will be observed. These differences are reflected in the compressibility index calculated 
by the formula. 
One of the important measures that can be obtained from bulk and tapped density 
determinations is the percent compressibility or the Carr’s index (I), which is determined 
by the following equation. 
 
 
9.3.2. Hausner ratio 
Hausner ratio is related to interparticle friction and, as such used to predict 
powder flow properties. 
 
 
 The compressibility index [Carr’s index (%)] is an indication of changes that occur in 
the packing arrangement while tapping the powder and is a direct measure of the 
propensity of a powder to consolidate when undergoing vibration, shipping and 
handling. Table shows that the compressibility index was the highest for all the 
polymers which had poor, flow properties since higher values tend to indicate poor 
flowability of powders. As per Table, higher values for Hausner ratio and angle of 
repose indicate poor flow properties of the polymers. This data suggests the need for 
granulation. 
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Table No.9 : % Compressibility values and Hausner ratio and its significance 
 
% Compressibility Flow character Hausner ratio 
<10 Excellent 1.00 -1.11 
11-15 Good 1.12 – 1.18 
16-20 Fairly  1.19 -1.25 
21-25 Passable 1.26 -1.34 
26-31 Poor 1.35 – 1.45 
32 -37 Very poor 1.46 -1.59 
>38 Very, very poor >1.60 
 
9.3.3. Melting point 
It is one of the parameters to judge the purity of crude drug. In case of pure 
chemicals, melting points are very sharp and constant. 
Procedure 
A small quantity of powder was placed into a fusion tube. That tube is placed in 
the melting point apparatus containing castor oil. The temperature of the castor oil was 
gradual increased automatically and read the temperature at which powder started to melt 
and the temperature when all the powder gets melted. The results are shown in results and 
discussion. 
 
9.4. SOLUTION PROPERTIES 
9.4.1. pH of the solution 
Weighed and transferred accurately about 1.0 g of sample in a 200ml clean and 
dried beaker, dissolved in carbondioxide free water and made up the volume to 100ml 
with same solvent, mixed.  Read the pH of freshly prepared solution by using 
precalibrated pH meter. The results are shown in results and discussion. 
 
9.4.2. Solubility 
A semi quantitative determination of the solubility was made by adding solvent in 
small incremental amount to a test tube containing fixed quantity of solute of vice versa. 
After each addition, the system is vigorously shaken and examined visually for any 
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undissolved solute particles. The solubility is expressed in terms of ratio of solute and 
solvent. The results are shown in results and discussion. 
 
9.5. IDENTIFICATION OF DRUG AND COMPATABILITY STUDY 
9.5.1. Drug –excipient compatibility studies 
 In the tablet dosage form the drug is in intimate contact with one or more 
excipients; the latter could affect stability of the drug. Knowledge of drug-excipient 
interactions is therefore very useful to the formulator in selecting appropriate excipients. 
This information is already be in existence for known drugs. For new drugs or new 
excipients, the pre formulations scientist must generate the needed information. 
By physical observation 
It was determined as per procedure given in method section the following table 
illustrated the result. 
 
Table.No. 10: Physical compatibility studies 
Test Observation Inference 
Physical compatibility No change of color These materials are 
compatible for formulation 
 
Procedure by FT-IR Studies 
The IR spectrums of nateglinide with excipients were taken by preparing dispersion in 
dry potassium bromide under dry condition. Superimposed these spectra. The 
transmission minima (absorption maxima) in the spectra obtained with the sample in 
corresponded in position and relative size to those in the spectrum obtained with the 
standards. 
 
9.6 UV SPECTROSCOPIC METHOD FOR ANALYSIS OF Nateglinide 
A. UV spectroscopy: (Determination of λ max) 
Nateglinide was accurately weighed and dissolved in the solvent (Phosphate 
buffer 6.8) to obtain solution of 100µg/ml. UV spectrum was run from 200-400nm and 
λmax was recorded using UV spectrophotometer. 
9.2.3. Preparation of calibration curve of nateglinide 
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 Nateglinide solution of 100µg/ml was prepared in phosphate buffer pH 6.8 and 
UV spectrum was recorded in the wavelength range from 200-400 nm. 
Standard stock solution: 100 mg of nateglinide was accurately weighed and transferred 
to 100ml volumetric flask and dissolved in phosphate buffer pH 6.8 to get solution of 
concentration 1000 µg/ml and this solution was further diluted suitably to get solution of 
concentration 50 µg/ml.   
Working stock solution: A series of nateglinide solutions ranging from 5 to 30 µg/ml was 
prepared from standard stock solution in phosphate buffer pH 6.8. The absorbance of all 
solutions was measured against phosphate buffer pH 6.8 as blank at 210 nm using UV 
spectrophotometer. Beer’s law was obeyed in the concentration range of 5-30 µg/ml. The 
high values of regression coefficient (0.9992) estimated the linearity of relationship 
between concentration and absorbance. 
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Table.No. 11: Calibration curve for nateglinide 
S.No. Concentration(µg/ml) Absorbance (nm) 
1 0 0 
2 5 0.145 
3 10 0.297 
4 15 0.459 
5 20 0.591 
6 25 0.729 
7 30 0.873 
Slope 0.0294  
 
0.9992  
 
Fig.No.9: Calibration curve of nateglinide in phosphate buffer pH 6.8 
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10. FORMULATIONS OF SUSTAINED RELEASE MATRIX 
TABLETS OF NATEGLINIDE  
10.1. Selection of method116. 
A. Direct compression 
The most common and simplest method available for tablet preparation is direct 
compression in which the drug with other excipients is mixed thoroughly with the help of 
various mixers followed by the compression of the resulting powder.  
All the polymers selected were found to be not directly compressible, hence the 
wet granulation was tried. 
B. Wet granulation 
Wet granulation is the most famous, complex but reliable method of granulation. 
Most of the drugs can be granulated by this method. It includes the use of a solvent to 
form a wet mass of drug and excipients together followed by the drying and lubrication. 
In this, the drug and excipients are mixed together in a geometric progression pattern and 
the mixture is then wet massed with the addition of volatile solvent. This wet mass is then 
passed through the appropriate mesh size to obtain the granules which were dried, 
evaluated and finally compressed to get tablet.  
 
 
 
 
  
   
  
 
 
 
 
 
 
                                 Fig..No.10: Flow diagram of wet granulation procedure 
Drug  Hydrophilic natural gum 
Wet mass using Iso propyl 
alcohol (IPA) 
Drying at 400C for 10-15 minutes 
Final granules 
Compression 
Sieving through 18 # sieve   
Lubricant, Glidant and Diluent  
CHAPTER-10                                                                                 FORMULATION  
 
   
Dept. of Pharmaceutics              67          J.K.K.Nattraja College of Pharmacy 
 
10.2. Preparation of hydrophilic matrix tablets 
A. Study of various gums and its different concentration levels 
        The natural gums like k – carrageenan, λ - carrageenan and locust bean gum were 
selected for the preparation of tablets and their concentrations in the formulations ranging 
from different ratios were used. 
 
B. Procedure for preparation of matrix tablet117: 
 Accurately weighed quantity of drug (nateglinide) and polymer were passed 
through 40# sieve. 
 The polymer and the drug were then mixed in a mortar by geometric progression 
for a period of 10-15 minutes. 
 This mixture was then granulated with isopropyl alcohol, and sieved using 18# 
sieve. Obtained granules were then dried in hot air oven at 400C for 10-15 minutes. 
 The dried granules were mixed with magnesium stearate and colloidal silicon 
dioxide and lactose monohydrate for further 2 minutes and compressed under 
10mm std. concave punch. 
 
10.2. 1. K – carrageenan 
Table No.12: Composition of k - carrageenan based  
matrix tablets of nateglinide 
Ingredients F1  F2  F3  
Nateglinide 120 120 120 
K - carrageenan 90 105 120 
Colloidal silicon dioxide 3 3 3 
Magnesium stearate 3 3 3 
Lactose monohydrate 78 63 48 
PVP K – 30 6 6 6 
 
                             *All the quantities are in mg 
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10.2. 2. λ- carrageenan 
Table No.13: Composition of λ- carrageenan based  
matrix tablets of nateglinide 
Ingredients F4  F5  F6  
Nateglinide 120 120 120 
λ- carrageenan 90 105 120 
Colloidal silicon dioxide 3 3 3 
Magnesium stearate 3 3 3 
Lactose monohydrate 78 63 48 
PVP K – 30 6 6 6 
                                                     *All the quantities are in mg 
 
10.2. 3. Locust bean gum 
Table No.14: Composition of locust bean gum based  
matrix tablets of nateglinide 
Ingredients F7  F8  F9  
Nateglinide 120 120 120 
Locust bean gum 90 105 120 
Colloidal silicon dioxide 3 3 3 
Magnesium stearate 3 3 3 
Lactose monohydrate 78 63 48 
PVP K – 30 6 6 6 
                                                     *All the quantities are in mg 
 
10.2.4. K – carrageenan + Locust bean gum 
A. K – carrageenan + Locust bean gum combinations 
From the results obtained by previous studies carried out using individual k – 
carrageenan 
 (F1 – F3) and locust bean gum as hydrophilic matrix (F7 – F9), the percentage  in which 
the k - carrageenan and locust bean gum combination could be used to formulate once a 
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day formulation of nateglinide was selected. The proportions of gum selected were 20:80, 
40:60, 50:50, 60:40, 80:20 as mentioned in the table no. 11. These ratios are in 
percentages of dry polymer weight i.e. 20% of k – carrageenan and 80% of locust bean 
gum in F10 and likewise for other ratios.    
Table No.15: Composition of k - carrageenan + locust bean gum combinations based 
matrix tablet of nateglinide 
Ingredients 
F10 
(20:80) 
F11 
(40:60) 
F12 
(50:50) 
F13 
(60:40) 
F14 
(80:20) 
Nateglinide 120 120 120 120 120 
K – carrageenan 24 48 60 72 96 
Locust bean gum 96 72 60 48 24 
Colloidal silicon 
dioxide 
3 3 3 3 3 
Magnesium stearate 3 3 3 3 3 
Lactose monohydrate 48 48 48 48 48 
PVP K - 30 6 6 6 6 6 
                                                *All the quantities are in mg 
B. K - carrageenan + Locust bean gum 40:60 combinations 
From the results obtained in above study, 40:60 ratio of k – carrageenan: locust 
bean gum in F41 was chosen to reduce the total polymer concentration from the tablet. 
Now, formulations were formulated such that each formulation contains 12mg less 
polymer content than previous formulation. It means from F45 to F49, there is 10% less 
polymer concentration in each formulation i.e. F46 contains 12mg less polymer content 
than F45 and so on, to obtain the formulation giving once a day formulation of nateglinide 
containing least amount of polymer. 
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Table No.16: Composition of k – carrageenan + locust bean gum 40:60 combinations 
based matrix tablets of nateglinide 
Ingredients F15 F16 F17 F18 F19 
Nateglinide 120 120 120 120 120 
K - carrageenan 21.6 19.2 16.8 14.4 12 
Locust bean gum 86.4 76.8 67.2 57.6 48 
Colloidal silicon dioxide 3 3 3 3 3 
Magnesium stearate 3 3 3 3 3 
Lactose monohydrate 60 72 84 96 108 
PVP K - 30 6 6 6 6 6 
                                                *All the quantities are in mg 
 λ – carrageenan + Locust bean gum 
A. λ – carrageenan + Locust bean gum combinations 
From the results obtained by previous studies carried out using individual  λ - 
carrageenan (F4 – F6) and locust bean gum as hydrophilic matrix (F7 – F9), the percentage  
in which the λ – carrageenan and locust bean gum combination could be used to 
formulate once a day formulation of nateglinide was selected. The proportions of gums 
selected were 20:80, 40:60, 50:50, 60:40, 80:20 as mentioned in the table no. 13. These 
ratios are in percentages of dry polymer weight i.e. 20% of λ – carrageenan and 80% of 
locust bean gum in F20 and likewise for other ratios.    
Table No.17: Composition of λ - carrageenan + locust bean gum combinations based 
matrix tablets of nateglinide 
Ingredients F20 (20:80) F21 (40:60) 
F22 
(50:50) 
F23 
(60:40) 
F24 
(80:20) 
Nateglinide 120 120 120 120 120 
λ – carrageenan 24 48 60 72 96 
Locust bean gum 96 72 60 48 24 
Colloidal silicon 
dioxide 3 3 3 3 3 
Magnesium stearate 3 3 3 3 3 
Lactose monohydrate 48 48 48 48 48 
PVP K – 30 6 6 6 6 6 
                                    *All the quantities are in mg 
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B. λ - carrageenan + Locust bean gum 20:80 combinations 
From the results obtained in above study, 20:80 ratio of λ – carrageenan: locust bean gum 
in F20 was chosen to reduce the total polymer concentration from the tablet. Now, 
formulations were formulated such that each formulation contains 12mg less polymer 
content than previous formulation. It means from F25 to F27, there is 10% less polymer 
concentration in each formulation i.e. F26 contains 12mg less polymer content than F25 and 
so on, to obtain the formulation giving once a day formulation of nateglinide containing 
least amount of polymer. 
Table No.18: Composition of λ – carrageenan + locust bean gum 20:80 combinations 
based matrix tablets of nateglinide 
Ingredients F25 F26 F27 
Nateglinide 120 120 120 
λ – carrageenan 21.6 19.2 16.8 
Locust bean gum 86.4 76.8 67.2 
Colloidal silicon dioxide 3 3 3 
Magnesium stearate 3 3 3 
Lactose monohydrate 60 72 84 
PVP K – 30 6 6 6 
                                                *All the quantities are in mg 
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11. EVALUATION OF MATRIX TABLETS OF NATEGLINIDE 
a) Pre-compression Studies: Micromeritic properties  
i) Angle of repose 
5 gms of the sample was taken in a funnel fixed in a holder (6 cm) above the 
surface at an appropriate height and graph of sheet was placed below the funnel. The 
sample was passed through the funnel slowly. The height of the powder heap formed was 
measured. The circumference of the heap formed was drawn with a pencil on the graph 
paper. The radius was measured and angle of repose was determined using the above 
formula. This was repeated five times for a sample. 
 
Where, 
h = height  
r = radius 
θ= angle of repose 
The results are given in results and discussion. 
ii) Determination of bulk density and tapped density 
A quantity 5gm of the powder (W) from each formula was introduced in to a 
25ml measuring cylinder. After the initial volume was observed, the cylinder was 
allowed to fall under its own weight on to a hard surface from the height of 2.5 cm at 2 
sec intervals. The tapping was continued until no further change in volume was noted. 
The bulk density and tapped density were calculated using the following the formula 
     Bulk density ( = m/  
  Tapped density( = ) = m/  
 
Where, 
m = mass of the powder 
 = initial or bulk volume 
   = final or tapped volume  
The results are given in results and discussion. 
 
θ= (h/r) 
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iii) Measurement of compressibility index and Hausner ratio 
           Compressibility index and Hausner ratio are measured by using the following 
formula 
     Tapped density-Intial bulk density 
%compressibility=x 100 
                    (carr’s index)                    Tapped density 
 
The result is given in in results and discussion. 
 
Hausner ratio= /  
Where, 
   = initial or bulk volume 
   = final or tapped volume 
 The results are given in results and discussion. 
 
11. Evaluation of matrix tablet 
11.1. Physical characterization of tablet  
A. Hardness114  
The resistance of tablets to shipping or breakage under conditions of storage,    
transportation and handling before usage depends on its hardness. The hardness of tablet 
of each formulation was measured by Monsanto hardness tester. The hardness was 
measured in terms of kg/cm2. 
B. Thickness 114 
Thickness and diameter of tablets were important for uniformity of tablet size.    
Thickness and diameter were measured using Vernier Calipers .   
C. Friability 114 
Friability is the measure of tablet strength. Roche friabilator was used for testing 
the friability using the following procedure. Ten tablets were weighed accurately and 
placed in the tumbling apparatus that revolves at 25 rpm dropping the tablets through a 
distance of six inches with each revolution. After 4 min., the tablets were weighed and 
the percentage loss in tablet weight was determined. 
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%	loss	 = 	
Initial	weight	of	tablets	– 	Final	weight	of	tablets
Initial	weight	of	tablets
	 
D. Uniformity of Weight118  
Weigh 10 tablets selected at random and calculate the average weight. Not more 
than two of the individual weights deviate from the average weight by more than the 
percentage shown in Table No. 15 and none deviates by more than twice that percentage. 
 
Table No.19. IP Standards of Uniformity of weight 
Sr. No. Avg. wt. of tablet % of deviation 
1 80 mg or < 80 10 
2 > 80 to < 250 mg 7.5 
3 > 250 or more 5 
 
E. Determination of drug content 119 
 Five tablets were weighed individually, then placed in a mortar and powdered with 
a pestle. 
 An amount equivalent to 50 mg drug (750 mg) was extracted in phosphate buffer 
pH 6.8 and shaken for 15 minutes.  
 The 2ml of this solution was again diluted to 10ml with phosphate buffer pH 6.8.  
This solution was then analyzed spectrophotometrically at 210nm. 
 
 11.2. Invitro studies  
 The USP type II dissolution apparatus was used to for vitro drug release study 
utilizing Dissolution System Lab india Analytical Instruments Pvt Ltd. Mumbai 
with a constant temperature water bath at 370C ± 10C.  
 The dissolution medium used was 0.2M phosphate buffer pH 6.8 (900ml) and the 
speed of rotation was kept 50 rpm.  
 6 ml of samples were collected after 1 hr. time interval and analyzed using UV 
spectrophotometer at 210 nm. 
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 Studies were performed in duplicate and the mean cumulative percentage of drug 
calculated (SD) and plotted against time. 
 
11.3. Determination of drug release kinetics 
To describe  the  kinetics  of  the  drug  release  from  the  sustained release  
matrix tablets, mathematical models such as Zero-order, First-order,  Higuchi & 
Korsmeyer-peppas models the release data were evaluated by model-dependent (curve 
fitting) method. Correlation coefficient ( ) values were calculated for linear curves 
obtained by the regression analysis of the above plot. 
Zero-order kinetic model –Cumulative % drug released vs. time 
First order kinetic model -log cumulative % drug remaining vs. time 
Higuchi model -Cumulative % drug released vs. square root of time 
Korsemeyer-peppas model -log cumulative % drug released vs. log time 
Zero order- kinetic model 
                            Zero order release would be predicted by the following equation.  
 
        Where, 
   -               Drug release at time‘t’ 
-               Initial drug concentration 
   -               Zero order rate constant ( ) 
      When the data plotted as cumulative % drug release time and the plot is linear , 
then the data obeys Zero-order equal to . 
 
First order kinetics 
     First order release would be predicted by the following equation 
 
 
 
Where, 
Log C -         Amount of drug remained at time ‘t’ 
 -         initial drug concentration 
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K        -        first order rate constant ( ) 
      When the data plotted as log cumulative % remaining time yields a straight line, 
then the release obeys first order kinetics. The constant ‘K’obtained by multiplying 2.303 
with the slope values. 
 
Korsemeyer-peppas model. 
        To study the mechanism of drug release from microspheres, the invitro data were 
fitted to the well known exponential equation (korsemeyerpeppasmodel ) which is often 
used to describe the drug release behavior from polymeric systems. 
 
Where,  
              Mt/Mα -    The fraction of drug released at ‘t’ 
              K          -     Constant incorporating structural and geometrical characteristics of  
the drug / polymer system  
               n         -        Diffusion exponent related to mechanism the drug release 
When the data plotted as log % drug released log time yields a straight line with a 
slope equal to ‘n’ and the K can be obtained by y- intercept. 
Mechanism of drug release as per korsemeyer-peppas equation / peppas model 
Table 20.Mechanism of drug release 
S . No n values Drug release 
1 0-0.5 Fickian release 
2 0.5-1.0 Non-Fickian release 
3 >1.0 Class II transport 
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12. RESULTS AND DISCUSSIONS 
PRE FORMULATION STUDIES 
Organoleptic properties 
            These tests were performed as procedure given, Preformulation part. The results 
are illustrated in following table. 
Table 21. Organoleptic properties 
Test Specifications/limits Observations 
Color White, Crystalline powder  White, Crystalline powder  
Odour Odorless, Bitter taste Odorless, Bitter taste 
The results complies as per specifications 
 
Angle of repose 
             It was determined as per procedure preformulation in material and method part. 
The results are illustrated in following table. 
Table 22. Flow properties 
Material Angle of repose 
Nateglinide 27°.14” 
 The result shows that drug having poor flow 
 
Bulk density and tapped density. 
             It was determined as per procedure given preformulation in material and method 
part. The results are illustrated in table. 
Table 23. Density 
Materials Bulk Density(gm/ml) Tapped density(gm/ml) 
Nateglinide 0.19 0.26 
 
 
Powder compressibility 
             It was determined as per procedure given in preformulation in material and 
method part. The results are illustrated in table. 
Table 24. Powder compressibility 
Material Compressibility index Hausner ratio 
Nateglinide 31.42% 1.18 
The results shows that drug having poor flow property 
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Melting point 
             It was determined as per procedure given in preformulation in material and 
method part. The results are illustrated in following table. 
Table 25. Melting point 
Material Material point range result 
Nateglinide 137 °C Complies 
 The result complies as per specification. 
 
SOLUTION PROPERTIES 
pH of the solution 
             It was determined as per procedure given in preformulation in material and 
method part. The results are illustrated in following table. 
Table 26. pH 
Material Test Specification Observation 
Nateglinide pH 6.5 6.5 
The result complies as per specification 
 
Solubility 
It was determined as per procedure given in preformulation in material and 
method part. The results are illustrated in following table. 
 
Table 27. Solubility 
Test Specification Result 
solubility 
soluble in methanol, ethanol, 
chloroform, dissolved in acetone, 
ethyl ether, almost insoluble in 
water. 
Complies 
The result complies as per specification. 
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DRUG-EXCIPIENT COMPATABILITY STUDIES 
Discussion:  
Drug excipient interactions play a vital role with respect to release of drug from 
formulation amongst others. FTIR techniques have been used here to study the physical 
and chemical interaction between drug and excipient used.  
 
Table 28. Drug – Excipients Compatibility Study Results 
Drug + Excipients Initial 
After 1 month at 
Compatible 
400C/75%RH 600C 
Drug White powder No change No change Yes 
Drug + K- Carrageenan White powder No change No change Yes 
Drug + λ- Carrageenan White powder No change No change Yes 
Drug + Locust bean 
gum 
White powder No change No change Yes 
Drug + Excipients White powder No change No change Yes 
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IR GRAPHS 
 
Fig. 11(a) FT-IR of Nateglinide  
 
 
Fig. 11(b) FT-IR Graph of Formulation 
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Table.No.29: Band  Assignments for the Infrared Absorption Spectrum                              
of Nateglinide 
Band Energy  (cm-1) Assignment 
1280 - 1431 
1651 
2866 - 3047 
1714 
3298 
1296 
1446 
3296 - 3311 
carboxyl, carboxylate 
carbonyl 
C-H stretching 
C=O 
N-H stretching 
C-O stretching 
C-O-H stretching 
N-H stretching 
In the present study, it has been observed that there is no chemical interaction 
between nateglinide and the polymers used. From the figures 11(a) and 11(b) it was 
observed that there were no changes in these main peaks in IR spectra of mixture of drug 
and polymers, which show there were no physical interactions because of some bond 
formation between drug and polymer.  
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PRECOMPRESSION STUDIES: 
EVALUATION OF TABLETS: 
Table No 30: EVALUATION OF GRANULES: 
Batch 
NO. 
Angle of 
Repose(°) 
Bulk 
Density 
(g/ml) 
Tapped 
Density(g/ml) 
Carr’s 
Index 
(%) 
Huasner 
Ratio 
F1 21°32′ 0.2574 0.3201 10.17 1.09 
F2 22°54′ 0.2641 0.3279 10.31 1.07 
F3 21°52′ 0.2678 0.3245 9.96 1.08 
F4 28°37′ 0.2745 0.3360 10.12 1.07 
F5 27°31′ 0.2792 0.3374 14.78 1.12 
F6 26°87′ 0.2748 0.3350 13.89 1.16 
F7 24°63′ 0.2749 0.3369 13.97 1.14 
F8 24°67′ 0.2801 0.3374 13.45 1.13 
F9 23°14′ 0.2841 0.3403 13.78 1.11 
F10 25°47′ 0.2814 0.3407 14.07 1.09 
F11 26°92′ 0.2874 0.3464 14.74 1.09 
F12 24°85′ 0.2799 0.3542 14.07 1.16 
F13 25°03′ 0.2745 0.3571 14.95 1.11 
F14 24°31′ 0.2868 0.3498 14.64 1.12 
 
Table No 31: EVALUATION OF GRANULES: 
Batch 
NO. 
Angle of 
Repose(°) 
Bulk 
Density 
(g/ml) 
Tapped 
Density(g/ml) 
Carr’s 
Index 
(%) 
Huasner 
Ratio 
F15 26°03′ 0.2823 0.3123 09.32 1.12 
F16 26°47′ 0.2831 0.3214 10.95 1.13 
F17 27°09′ 0.2932 0.3675 10.47 1.14 
F18 26°91′ 0.2945 0.3374 11.31 1.12 
F19 27°33′ 0.2846 0.3235 12.29 1.09 
F20 27°93′ 0.2753 0.3492 12.45 1.17 
F21 28°17′ 0.2785 0.3345 12.78 1.16 
F22 28°54′ 0.2714 0.3975 12.64 1.18 
F23 29°08′ 0.2681 0.3374 13.74 1.11 
F24 28°02′ 0.2574 0.3312 13.17 1.13 
F25 26°51′ 0.2968 0.3607 14.71 1.12 
F26 26°75′ 0.2734 0.3471 14.46 1.16 
F27 27°92′ 0.2789 0.3682 14.09 1.17 
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Discussion 
The angle of repose for the formulations F1-F27 was found to be in the range 21°32′ to 
29°08′ shows good flow property 
          Compressibility index for the formulations F1-F10 found between 09.32% to 
14.95% indicating the good flow property. 
Huasner Ratio for the formulations F1-F10 found between 1.07 to 1.18 indicating 
the good flow property. 
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EVALUATION OF NATEGLINIDE TABLETS: 
 
Table. No: 32.WEIGHT VARIATION AND FRIABILITY: 
Batch. 
No 
Weight Variation 
(%) Friability (%) 
Thickness 
(mm) 
Hardness 
(Kg/cm2) 
F1 301±1.52 0.21 4.12±0.2 8.07 
F2 304±2.37 0.23 4.03±0.2 7.92 
F3 298±1.44 0.33 4.22±0.1 8.14 
F4 320±1.86 0.42 4.31±0.1 7.54 
F5 312±2.56 0.41 4.07±0.1 7.92 
F6 303±2.13 0.23 4.12±0.1 7.61 
F7 304±1.52 0.24 4.06±0.2 7.47 
F8 318±1.49 0.20 4.19±0.3 7.42 
F9 290±2.37 0.18 4.38±0.2 8.10 
F10 312±1.91 0.25 4.12±0.1 8.32 
F11 309±1.34 0.24 4.16±0.2 8.23 
F12 317±2.03 0.35 4.14±0.2 8.14 
F13 309±1.92 0.27 4.23±0.2 7.76 
F14 303±1.66 0.52 4.08±0.1 7.91 
 
Table. No: 33.WEIGHT VARIATION, FRIABILITY THICKNESS & HARDNESS  
Batch. 
No 
Weight Variation 
(%) Friability (%) 
Thickness 
(mm) 
Hardness 
(Kg/cm2) 
F15 320±2.12 0.16 4.01±0.1 8.09 
F16 309±1.03 0.34 4.03±0.1 8.32 
F17 314±1.47 0.31 4.12±0.2 8.14 
F18 306±1.42 0.24 4.62±0.3 8.45 
F19 313±2.03 0.23 4.03±0.1 8.15 
F20 312±1.74 0.29 4.08±0.2 7.92 
F21 303±1.92 0.41 4.31±0.2 7.65 
F22 291±2.04 0.36 4.26±0.1 8.19 
F23 289±1.92 0.24 4.12±0.3 8.74 
F24 301±1.25 0.31 4.14±0.2 8.31 
F25 316±1.36 0.17 4.19±0.2 8.47 
F26 303±1.23 0.24 4.27±0.1 8.23 
F27 301±1.82 0.29 4.21±0.1 8.35 
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Discussion:  
The weight variation of the tablet in the range of ± 1.03 % to ± 2.37 % ( below 
5%) complying with pharmacopoeial specification. 
The friability of the tablet in the range of 0.16 % to 0.52% (below 1%) complying 
with pharmacopoeial specifications. 
The thickness of the formulations from F1- F12 was found to be in the range of 
4.01±0.1 to 4.31±0.2 and hardness of the formulated tablets was found to 7.42 to 8.74 
indicating a satisfactory mechanical strength for the sustained release.  
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12.1.2. K – Carrageenan 
The drug release from the k – carrageenan matrices is dependent upon the extent 
of swelling and the formation of gel layer on the matrices. As the concentration of k – 
carrageenan increases in matrix from F1 – F3, the extent of swelling and the thickness and 
viscosity of the gel layer increases. The inverse relationship between drug release and 
swelling was observed.  Initially drug release from k – carrageenan matrices was slow 
due to rapid hydration and swelling of the matrices. F3 shows the once a day release from 
the matrix tablet while,
 
F1 & F2 showed the premature drug release. It was found that as 
the amount of gum in the matrix increased, there was a greater degree of gum hydration 
with simultaneous swelling. This would result in lengthening of the drug diffusion 
pathway and drug release rate would go on decreasing. This is due to the fact that the 
erosion rate from F2 & F3 matrices was very fast as compared to F3 as it contains lower 
concentration of polymer. 
Table.No. 34. In vitro drug release profile of F1 – F3 
Time (hours) BATCH NO. F1 F2 F3 
1 8.20 7.48 8.53 
2 18.39 13.52 19.03 
4 26.08 25.11 26.15 
6 39.72 39.58 31.96 
8 53.79 45.09 36.61 
10 69.13 51.44 44.13 
12 78.51 58.19 51.83 
14 86.40 63.52 59.44 
16 92.16 76.43 69.97 
18  83.10 75.44 
20  91.30 81.39 
22   89.55 
24   96.21 
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Fig 12. In vitro drug release profile of F1 – F3 
 
 
12.1.3 λ – Carrageenan 
The drug release from the λ - carrageenan matrices is dependent upon the extent 
of swelling of the matrices. As the concentration of λ – carrageenan increases in matrices 
from     F4 – F6, swelling increases and drug release rate decreases from the matrices i.e. 
there was an inverse relationship between drug release and swelling.  Initially drug 
release from λ – carrageenan matrices was slow due to rapid hydration and swelling of 
the matrices. F6 showed the once a day release and F4 and F5 showed the premature drug 
release.  The λ – carrageenan matrices do not shows the gelation capacity hence the drug 
release from these matrices does not depends upon the gel layer formation but on extent 
of swelling. Matrix erodibility is related to polymer solubility, also seems to be a useful 
property for obtaining linear drug release profiles. In fact, matrix erosion limits the 
increase in the diffusional pathway and avoids the decrease of release rate with time. It is 
also conceivable that the higher the percentage of λ- carrageenan in the formulation, the 
stronger the effect of its dissolution behaviour on the attrition rate of the matrix. 
 
 
 
 
 
CHAPTER-12                                                              RESULTS & DISCUSSION  
  
Dept. of Pharmaceutics               88        J.K.K.Nattraja College of Pharmacy 
 
Table.No. 35. In vitro drug release profile of F4 – F6 
Time (hours) BATCH NO. F4 F5 F6 
1 10.32 11.59 14.53 
2 18.69 19.77 19.22 
4 29.03 28.13 27.90 
6 40.12 37.12 34.22 
8 47.39 45.33 41.56 
10 53.12 51.97 49.29 
12 65.44 58.20 56.33 
14 74.70 64.66 63.70 
16 87.53 76.23 70.08 
18 92.39 85.40 78.54 
20  93.56 84.89 
22   91.05 
24   98.89 
Fig 13. In vitro drug release profile of F4-F6 
 
 
12.2. Locust bean gum [LBG] 
The drug release from the LBG matrices is dependent upon the gel layer thickness 
and viscosity of the gel layer. Being hydrophilic in nature, LBG, after hydration and 
swelling, goes into solution or erodes. Thus, the overall dimensions of the matrices are 
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affected by the rate of swelling and that of dissolution/erosion. As the concentration of 
the LBG increases in the matrix from F7 – F9, the diameter of the tablet was found to 
increase progressively and a distinct gel-sol boundary develops and the rate of erosion 
decreases due to formation of viscous and thick gel layer. Hence, retardation of drug 
release increases from the matrices F7 – F9. In the case of LBG matrices, a rate of erosion 
of the hydrated layer was significant as compared to other galactomannans (guar gum), 
thus requiring 40% polymer concentration to retard the drug release for 24hrs.  
Table.No. 36. In vitro drug release profile of F7 – F9 
Time (hours) BATCH NO. F7 F8 F9 
1 09.68 11.27 08.32 
2 21.33 25.41 14.71 
4 30.21 39.17 21.07 
6 41.96 47.14 30.82 
8 53.22 54.41 39.71 
10 64.56 60.19 48.27 
12 72.39 69.02 55.14 
14 80.66 76.41 61.63 
16 91.53 82.50 70.24 
18  90.47 79.14 
20  96.74 84.33 
22   90.56 
24   97.19 
Fig.14. In vitro drug release profile of F7 – F9 
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12.2.1K – carrageenan + Locust bean gum 
A. K – carrageenan + Locust bean gum combinations 
K – carrageenan and locust bean gum are swellable gel forming polymers. On 
contact with aqueous medium k – carrageenan and locust bean gum matrix gradually 
begins to hydrate from the periphery towards the centre, forming a gelatinous swollen 
mass, which controls the diffusion of drug molecules through the polymeric material into 
aqueous medium. The hydrated gel layer thickness determines the diffusional path length 
of the drug. The in vitro drug release profiles of nateglinide from matrices containing k – 
carrageenan and locust bean gum in different gum proportions (F10 – F14) were shown in 
fig..  From the fig., it is clear that, the drug release was more retarded in k – carrageenan 
and locust bean gum combination matrices than individual k – carrageenan (F1 – F3)and 
locust bean gum matrices (F7 – F9). K – carrageenan swells fast initially and forms gel 
quickly and locust bean gum swells slowly and steadily. From the fig., it can be seen that, 
the maximum retardation of drug has been observed in F10 which contains the 40:60 ratio 
of k – carrageenan: locust bean gum. This might be due to the synergistic interaction 
between these two gums to produce a strong and elastic gel around the core of the 
matrices retarding the drug release from the matrices. As we go on increasing or 
decreasing the concentration of k – carrageenan or locust bean gum, the retardation 
efficiency of drug release from the matrices was found to go on decreasing. This might be 
due to the fact that the synergistic interaction between two gums goes on decreasing as 
we increased either of gum concentration in formulation. As the locust bean gum 
concentration decreases in F10 from F11 there is increase in drug release from 68.88% 
(F11) to 71.45% (F10) at t24h. It was found that there was not much increase in drug 
release in F10. This might be due to the fact that there was not much decrease in 
synergistic interaction, ultimately not reducing the thickness and viscosity of the gel layer 
to a much extent. When the k – carrageenan concentration was increased from F11 to F14, 
it was observed that the drug release from the matrix was increased from 68.88% (F11) to 
80.75% (F12), 88.15 (F13), and 95.87% (F14) at t24h. This increased drug release from F11 
to F14 might be due the fact that k – carrageenan and might be due to the formation of less 
strong and elastic gel.    
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Table.No. 37. In vitro drug release profile of F10 – F14 
Time (hours) BATCH NO. F10 F11 F12 F13 F14 
1 6.24 05.93 09.62 10.47 8.21 
2 10.41 09.14 14.27 16.21 17.43 
4 16.70 13.42 19.43 23.83 24.71 
6 21.51 19.74 24.17 29.72 31.84 
8 26.07 24.34 29.82 36.14 39.81 
10 30.74 29.91 35.07 41.57 45.77 
12 36.14 33.40 40.33 47.13 52.86 
14 41.29 39.72 48.64 54.71 61.28 
16 46.30 45.81 54.73 60.43 69.56 
18 50.47 51.34 60.81 69.57 76.25 
20 58.67 56.17 69.40 73.14 83.17 
22 65.12 62.55 74.21 81.57 90.74 
24 71.45 68.88 80.75 88.15 95.87 
Fig.15. In vitro drug release profile of F10 – F14 
 
 
B. K - carrageenan + Locust bean gum 40:60 combinations 
 It is clear that the drug release from the k – carrageenan and locust bean gum 
combination matrices depends upon the formation of gelatinous swollen mass and its 
thickness which determines the diffusional path length of the drug to diffuse out from the 
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matrix into dissolution medium. The in vitro drug release profiles of nateglinide from k – 
carrageenan and locust bean gum combination matrices (F15 – F19) are shown in fig. From 
the fig, it can be clearly seen that, as the concentration of total dry polymer decreases in 
the formulation, the drug release from the matrix goes on increasing. This suggests that 
there is inverse relationship between drug release and polymer concentration. As the 
polymer concentration decreases in the matrix, the formation of swollen gelatinous mass 
and thickness of that formed swollen mass decreases. This might be the reason for the 
increased drug release from the matrix. The drug release from the formulations F15 – F17 
is 79.51% (F15), 88.44% (F16) and 98.90% (F17) at t24h and 99.21% (F18) at t22h and 
101.83% (F19) at t20h. As the formulation F17 showed the drug release upto t24h i.e. it 
formed the once a day sustained release formulation of nateglinide. This means that the 
30% (36mg) of polymer concentration of was reduced from the formulation.   
Table.No. 38. In vitro drug release profile of F15 – F19 
Time (hours) BATCH NO. F15 F16 F17 F18 F19 
1 05.31 09.17 10.71 12.42 16.88 
2 11.78 14.24 19.22 20.71 25.40 
4 19.26 20.14 27.34 27.48 32.46 
6 25.87 29.14 34.19 33.85 44.58 
8 31.74 36.72 40.28 40.24 52.86 
10 39.45 41.34 48.17 49.33 60.44 
12 44.67 47.60 55.83 56.81 69.14 
14 50.41 54.12 61.24 64.27 74.65 
16 58.62 60.71 69.17 75.08 80.19 
18 63.77 69.48 76.57 83.72 86.17 
20 69.12 74.52 85.14 91.47 92.12 
22 73.20 80.12 92.12 99.21 101.83 
24 79.51 88.44 98.90   
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Fig.16. In vitro drug release profile of F15 – F19 
 
 
12.2.2 λ – carrageenan + Locust bean gum 
A. λ – carrageenan + Locust bean gum combinations 
Carrageenans are a group of sulphated polymers consisting of galactose residues. 
The degree of sulphate esterification especially affects the gelation properties of the 
polymer. In particular, λ - carrageenan has a higher degree of esterification, does not 
show gelation capability but it hydrates and swells to a good extent. Locust bean gum is 
swellable gel forming polymer. Hence, by combining these two polymers they formed 
swellable gelatinous layer. The hydrated gel layer thickness determines the diffusional 
path length of the drug and ultimately the drug release. The in vitro drug release profiles 
of nateglinide from tablets containing λ – carrageenan and locust bean gum in different 
gum proportions (F20 – F24) are shown in fig.17. From the fig.17, it is clear that, the drug 
release was more retarded in λ – carrageenan and locust bean gum combination matrices 
(F20 – F24) than individual λ – carrageenan (F4 – F6) and locust bean gum matrices (F7 – 
F9). As mentioned above λ- carrageenan hydrates and swells fast but it do not forms the 
gel. Hence, the drug release initially controlled due to the swelling of   λ- carrageenan 
and then the formation of swellable gelatinous layer by locust bean gum. From the fig.17, 
it can be seen that, the maximum retardation of drug has been observed in F20 which 
contains the 20:80 ratio of λ – carrageenan: locust bean gum. This might be due to the 
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synergistic interaction between these two gums to produce a strong and elastic gel around 
the core of the matrices retarding the drug release from the matrices. From the in vitro 
release profile of F20 – F24  it can be seen that, as we increased the concentration of the λ 
– carrageenan from formulation (F20 – F24), the drug release from the matrices increased. 
When the λ – carrageenan concentration was increased from F20 to F24, it has been 
observed that the drug release from the matrix was increased from 77.68% (F20) to 
83.65% (F21), 90.40% (F22) at t24h and 99.6% (F23) at t23h and 101.63% (F24) at t20h. As 
the λ – carrageenan does not form gel but swells hence; erosion is predominant with it as 
compared to the swellable gel forming polymers such as locust bean gum. Also, as the λ 
– carrageenan concentration increases in the formulation, locust bean gum concentration 
decreases, the thickness and the viscosity of the gel layer around the tablet decreases. 
This might be the contributing factor for the increased drug release from F20– F24.  
 
Table.No. 39. In vitro drug release profile of F20 – F24 
Time (hours) BATCH NO. F20 F21 F22 F23 F24 
1 11.78 13.37 12.44 16.41 19.74 
2 18.35 19.12 18.75 22.77 29.45 
4 24.89 26.22 24.22 30.22 36.88 
6 29.08 33.64 30.95 39.72 43.95 
8 34.24 38.09 36.74 45.21 51.93 
10 39.96 44.78 42.33 51.17 59.48 
12 44.47 49.08 50.87 59.84 66.85 
14 50.78 53.57 59.24 66.30 74.24 
16 57.20 59.74 65.85 74.81 81.75 
18 62.28 65.51 71.39 80.17 92.24 
20 69.14 71.92 78.09 92.28 101.63 
22 71.45 77.69 84.33 99.61  
24 77.68 83.65 90.40   
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Fig.17. In vitro drug release profile of F20 – F24 
 
 
B. λ - carrageenan + Locust bean gum 20:80 combinations 
 It is clear that the drug release from the λ – carrageenan and locust bean gum 
combination matrices, depends upon the formation of gelatinous swollen mass and its 
thickness which determines the diffusional path length of the drug to diffuse out from the 
matrix into dissolution medium. The in vitro drug release profiles of nateglinide from λ – 
carrageenan and locust bean gum combination matrices (F25 – F27) are shown in fig.18. 
From the fig.18, it can be clearly seen that, as the concentration of total dry polymer 
decreased in the formulation, the drug release from the matrices goes on decreasing. The 
drug release from the formulations F25 – F26 is 88.05% (F25), 97.75% (F26) at t24h and 
102.35% (F27) at t22h. As the concentration of total dry polymer decreases in the 
formulation, the thickness and the viscosity of the gel layer goes on decreasing. This 
causes to decrease the diffusional path length for the drug to diffuse out from the dry core 
of the matrix. This might be the reason for the decreased drug release from the matrix 
formulation. As the formulation F26 sustained the drug release upto t24h i.e. 20% (24mg) 
of polymer concentration of was reduced from the formulation.   
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Table.No. 40. In vitro drug release profile of F25 – F27 
Time (hours) BATCH NO. F25 F26 F27 
1 08.31 10.47 16.48 
2 13.45 16.17 22.64 
4 19.97 21.08 30.47 
6 24.63 26.65 39.38 
8 30.24 39.14 47.08 
10 38.22 48.92 54.22 
12 42.38 54.67 61.84 
14 50.52 61.07 69.22 
16 59.22 69.24 76.54 
18 68.54 76.72 81.26 
20 74.91 84.24 87.92 
22 81.65 91.02 94.24 
24 88.05 97.75 102.35 
 
Fig.18. In vitro drug release profile of F25 – F27 
 
6.3.4.3. K - carrageenan [Fig. 16, F3] 
Looking at the swelling behavior of the tablets F3, first the carrageenans swells 
relatively fast with consequent formation of a gel layer and then swelling slows (fig.19). 
The responsibility for this behavior is the higher mobility of the water molecules between 
the polymer chains; they can penetrate more easily because there are fewer sulfate 
groups, binding water tightly in solvate form at the chains [102]. It was observed that the 
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within 1h about 200% (axial swelling, fig.20.B) of the initial value and 130% (radial 
swelling, fig.20.C) of the initial value was reached. As the water uptake of k - 
carrageenan matrix tablet (F3) was rapid, the swelling slowed drug release was observed 
from F3 from the 1h itself. The gel layer (rubbery state) grows with time as more water 
permeates into the core of the matrix, thereby increasing the thickness of the gel layer and 
providing a diffusion barrier to drug release. When F3 gets fully hydrated with axial 
swelling 375% (fig.13.B) and radial swelling 190% (fig.13.C) in 6h, the gel layer slowly 
dissolved and started eroding away exposing a new gel layer as is commonly observed 
with swellable matrix tablets.  
 
6.3.4.4. λ – carrageenan [Fig. 16, F6] 
λ – carrageenan is swellable polymer, does not show gelation capability due to 
high degree of sulfate esterification but it hydrates and swells to a good extent [108].  In 
case of F6, it was observed that during dissolution testing of the matrix tablets rapid 
surface hydration of the matrix F6 was observed which resulted in its swelling. The extent 
of swelling determines the diffusional path length for the drug to release from the matrix. 
It was observed that F6 swelled rapidly i.e. 196.07% (axial swelling, fig.16.B) of the 
initial value and 130% (radial swelling, fig.16.C) of the initial value was reached, 
retarding the drug release from the F6. As time progresses, the matrix drew more water 
inside and gets fully hydrated in 6h with axial swelling 416.66% (fig.16.B) and radial 
swelling of 190%, the glassy core starts diminishing and the tablet dimensions change in 
the axial and radial directions.         
  
6.3.4.5. Locust bean gum [Fig. 16, F9] 
 
LBG is a nonionic polysaccharide and the hydration process is independent of pH. 
When the formulation F3, is placed in the aqueous medium, liquid penetrates into the 
tablet and a gel is formed due to uncoiling of the structure of the locust bean gum 
molecules and the formation of hydrogen bonds with water molecules. As a result, the 
diameter of the tablet increases progressively and a distinct gel-sol boundary develops. It 
was observed that F6 swelled rapidly i.e. 165.09% (axial swelling, fig.19.B) of the initial 
value and 130% (radial swelling, fig.19.C) of the initial value was reached, which 
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indicates that the gum hydrated quickly and a sufficient boundary gel formed 
immediately retarding the drug release from the F9. This was visually observed during the 
experiment. As time progresses, the matrix dragged more water inside and gets fully 
hydrated in 6h with axial swelling 188.67% (fig.19B) and radial swelling of 130%, the 
glassy core starts diminishing and the tablet dimensions change in the axial and radial 
directions.   
 
Fig.19. A. Water uptake study of formulations, F3, F6 and F9 
B. Axial swelling study of formulations, F3, F6 and F9 
   C. Radial swelling study of formulations, F3, F6 and F9 
 6.3.4.8. K – carrageenan + Locust bean gum 
A. K – Carrageenan and locust bean gum combinations 
The water uptake and swelling behaviour of the k -carrageenan and locust bean 
gum combination matrices (F10 – F14) were investigated (fig.30) with a gum proportions 
which are shown in Table 18. As both k -carrageenan and locust bean gum are swellable 
gel forming polymers, they form highly thick and viscous gel layer increasing the 
A 
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diffusional path length thus, decreasing the drug release from the matrices. This increased 
thickness and viscosity of the gel layer also decreases the erosion rate of the matrix tablet. 
The change in weight is characteristic of the water uptake and swelling which started 
immediately and continued for 6h (fig.30). The F11 showed the maximum drug 
retardation with maximum water uptake (430.98%) and swelling (axial swelling 285.03% 
and radial swelling 190%). The k – carrageenan and locust bean gum (40:60) shows the 
viscous synergism in this ratio. This means that they forms the viscous gel layer more 
highly thick and viscous gel layer around the matrix tablet than there individual matrices 
would produce (F13 and F19). 
                               
 
   Fig.20. A. Water uptake study of formulations F10, F11, F12, F13 and F14 
               B.  Axial swelling study of formulations F10, F11, F12, F13 and F14 
                C.  Radial swelling study of formulations F10, F11, F12, F13 and F14 
 
 
B C 
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B. K – Carrageenan and locust bean gum 40:60 combinations 
The water uptake and swelling behaviour were investigated with the formulations 
mentioned in Table 19. The results water uptake and swelling studies of  k - Carrageenan 
and locust bean gum 40:60 combinations (F15 – F19) were shown in fig.31. From the 
fig.31, it can be concluded that, as the total concentration of polymer decreases in the 
formulation from F15 – F19, the water uptake and swelling of the matrices goes on 
decreasing. As the total dry polymer concentration decreases in formulation, the lactose 
concentration in formulation goes on increasing in the formulation from F15 – F19 (fig.31), 
the radial and axial dimensions of the matrix diminish along with the reduction in the 
matrix’s weight as the water absorption rate increases. The reason for this increased water 
uptake due to increased lactose in the formulation has been given in section 6.3.4.7.B. 
Hence, the drug release from the matrix goes on increasing from          F15 – F19 which can 
be seen from fig.22. The radial and axial expansion was almost constant after 6 h. This 
suggests the role of erosion to maintain constant diffusional path length because of proper 
synchronization between erosion and diffusion. The terminal water uptake and 
radial/axial swelling of F17 was less steep because the diffusional path length and distance 
to be traveled for dissolution media to reach the dry core increases with time. Hence, the 
drug release profile of F17 fits into the Korsmeyer – Peppas power law equation 
(anomalous behaviour, n – 0.8026).   
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       Fig.21. A. Water uptake study of formulations F15, F16, F17, F18 and F19 
                   B. Axial swelling study of formulations F15,F16, F17, F18 and F19 
                  C. Radial swelling study of formulations F15, F16, F17, F18 and F19 
6.3.4.9. λ – carrageenan + Locust bean gum 
A. λ - carrageenan and locust bean gum combinations 
The water uptake and swelling behaviour of the λ-carrageenan and locust bean 
gum combination matrices (F10 – F14) were investigated (fig.32) with different gum 
proportions which are shown in Table 20. λ -carrageenan is not a gel forming polymer, it 
only swells (hydrates) immediately when it comes in contact with water whereas locust 
bean gum is swellable gel forming polymer. When both the polymers were combined in a 
formulation, the erosion rate of the λ –carrageenan also decreases as locust bean gum 
forms viscous gel layer around the matrix tablet. The thickness and the viscosity of the 
gel layer determine the extent of drug release from the matrix. As it can be seen from the 
fig.32, the maximum swelling (axial swelling, 362.54%) and water uptake (402.09%) was 
C 
 
B 
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shown by F20, as was the drug release from the matrix. The λ - carrageenan and locust 
bean gum shows the viscous synergism in 20:80 ratio which suggests that the highly thick 
and viscous gel layer is formed by F20, which causes the drug release to be retarded 
maximum.    
 
 
 
 
                Fig.22.A. Water uptake study of formulations F20, F21, F22, F23 and F24 
                           B. Axial swelling study of formulations F20, F21, F22, F23 and F24 
                           C. Radial swelling study of formulations F20, F21, F22, F23 and F24 
  
B. λ - carrageenan and locust bean gum 20:80 combinations 
Measurement of swelling/hydration rates of different matrices were carried out to 
gain insight into the observed phenomena of drug release with the rates of polymer 
hydration and to evaluate the extent of water penetration into the tablets. Results of water 
uptake, axial and radial expansion for F25 – F27 are shown in fig.33. It is evident that 
water uptake was continuously rising for 6h until it gets fully hydrated. From the fig.33, it 
B 
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can be concluded that, as the total concentration of polymer decreases in the formulation 
from F25 – F27, the water uptake and swelling of the matrices goes on decreasing. As the 
total dry polymer concentration decreases in formulation, the lactose concentration in 
formulation goes on increasing in the formulation from F25 – F27 (fig.33), the radial and 
axial dimensions of the matrix diminish along with the reduction in the matrix’s weight 
as the water absorption rate increases. The reason for this increased water uptake due to 
increased lactose in the formulation has been given in section 6.3.4.7.B. Hence, the drug 
release from the matrix goes on increasing from F25 – F27 which can be seen from the F25 
– F27 (fig.33). The terminal water uptake and radial/axial swelling of F26 was less steep 
because the diffusional path length and distance to be traveled for dissolution media to 
reach the dry core increases with time. Hence, the drug release profile of F26 fits into the 
Korsmeyer– Peppas power law equation (anomalous behaviour, n – 0.7458)       
 
 
                                                               
                       
 
 
 
 
Fig.23.  A. Water uptake study of formulations F25, F26 and F27 
B. Axial swelling study of formulations F25, F26 and F27 
C. Radial swelling study of formulations F25, F26 and F27 
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12.3 Drug Release Kinetics 
The release of nateglinide from the matrices was evaluated by using PCP Disso 
V3 .To  evaluate  the  drug  release  kinetics,  formulations showing  a  significant  slow  
release  were  chosen.  In general, the mechanism of drug release from polymeric 
matrices can be described by the swelling phenomenon. The solvent molecules move 
inside the polymeric matrix like a “front”, simultaneously, the thickness of the area 
increases with time in the opposite direction. The mechanism of drug release can be 
described by a second phenomenon that involves the disentanglement and erosion of the 
polymer. By using the Korsmeyer and Peppas model equation, the n values were obtained 
between 0.65 and 0.97 for all formulations. These values are characteristic of anomalous 
kinetics (non Fickian) suggesting that more than one mechanism might be involved in the 
release kinetics. Here, the polymer relaxation and erosion are the rate-controlling steps. 
When n = 0.5, Fickian diffusion is the rate-controlling step (case I transport). Values of n 
between 0.5 and 1 indicate the contribution of both the diffusion process as well as 
polymer relaxation in controlling the release kinetics (non-Fickian, anomalous or first-
order release). When the exponent n takes a value of 1.0, the drug release rate is 
independent of time. This case corresponds to zero-order release kinetics (also termed as 
case II transport).  It should be noted that the two extreme values of n = 0.5 and 1 are 
only valid for slab geometry. For cylindrical tablets, these values range from 0.45 < n < 
0.89 for Fickian, Anomalous or Case II transport respectively. The Peppas model gave a 
good fit to most of the dissolution data of the swellable matrix tablets as shown by the 
R2values (0.9892 < R2 < 0.9968). For all the nateglinide matrix formulations, the 
contribution of polymer relaxation occurs throughout the entire dissolution period. This 
was also apparent from the n values obtained for selected formulations, which approach 
anomalous transport. In general, the relaxational contribution was higher for the 
formulations with higher n values. The k - carrageenan formulation (F3) showed the 
highest contribution of polymer relaxation. 
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Table.41. Drug release parameters for selected formulations 
Formulation n values R2 k values Best fit model 
F13 0.9748 0.9897 4.2354 Peppas 
F16 0.9448 0.9897 4.2416 Peppas 
F19 0.7997 0.9935 4.1579 Peppas 
F17 0.8026 0.9968 4.1625 Peppas 
F26 0.7458 0.9914 4.1145 Peppas 
 The regression coefficient values and n values show that the drug releases follow 
Non - Fickian release (Diffusion and swelling). 
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13. SUMMARY 
                          Nateglinide [N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine] 
is a novel, highly physiologic, mealtime glucose regulator approved for the treatment of 
type II diabetes mellitus. Nateglinide is a BCS class II (Insoluble, highly permeable) 
drug. The plasma half life of nateglinide is 1.5h and bioavailability of 73%. The usual 
oral dosage regimen is 60— 180mg taken 3 times a day for nateglinide immediate release 
tablets. The controlled or sustained release formulation of nateglinide would be more 
useful than the nateglinide immediate release tablets from the view point of avoidance of 
side effect, improvement of compliance to patients and to enable control of both post 
prandial blood glucose level and fasting blood glucose level for moderate and severe 
diabetes patients. Hence, an attempt was made to develop a sustained-release (SR) oral 
dosage form of nateglinide instead of IR tablet. 
The present work studied the natural polymer based once a day matrix tablet of 
nateglinide. From the wide range of hydrophilic polymers, k – carrageenan, λ – 
carrageenan and locust bean gum. Combinations of the two different gums  k-
carrageenan and locust bean gum and λ-carrageenan and locust bean gum were 
formulated in different ratios 20:80, 40:60, 50:50, 60:40 and 80:20 to exploit rheological 
synergism between two gums. Further the formulations were prepared dorm the 
formulation which exhibited maximum retardation such that each contains 10% less 
polymer concentration than the previous formulation in order to achieve the once a day 
matrix tablet of nateglinide containing least amount of polymer. The blends were 
prepared by non-aqueous wet granulation techniques with lactose as a diluent in 
formulations. The dried blends were compressed with other necessary excipients. The 
tablets were evaluated for hardness, thickness, drug content uniformity, in-vitro drug 
release studies for 24 hours (USP dissolution apparatus II, phosphate buffer-pH 6.8, 50 
rpm, 37±0.5ºC), water uptake studies, swelling studies and in  of the matrix tablet. The 
amount of Nateglinide released from the tablet formulations was estimated at 210nm 
using a UV spectrophotometer. The kinetic analysis of selected formulations were 
performed and found to follow Korsmeyer-Peppas model through non-fickian transport 
mechanism.  
The following conclusions can be drawn from the above study. 
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From the results obtained we can conclude that the polymers selected for the 
study, can be used individually for the sustained drug delivery of nateglinide locust bean 
gum was used in combination with k-carrageenan and λ-carrageenan in 60:40 and 20:80 
ratios respectively with least in vitro drug release and can be used to reduce the 
concentration of polymer from the tablet.30% polymer reduction in case of k-carrageenan 
and locust bean gum and 20% with λ-carrageenan and locust bean gum combination was 
achieved.  
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14. CONCLUSION 
      Once a day sustained release matrix tablets of nateglinide was prepared by 
using natural polymers k-carrageenan,lambda carrageenan and locust bean gum. Natural 
polymers were selected due to their easy availability and cheaper in coast and we can get 
standard uniformity and combinations of two different gums carrageenan and locust been 
gum were formulated in different ratios to exploit the rheological synergism between two 
gums in order to achive once a day matrix tablets of nateglinide further formulations were 
prepared from the formulations exhibited maximum retardation the controlled or 
sustained release formulations of nateglinide would be more useful than the nateglinide 
immediate release tablets from the new point of side effects improvement of compliance 
to patients and to enable to control of both post prandial blood glucose level and fasting 
blood glucose level for moderate and sever diabates patients.  
Hence an attempt was made to develop a sustained release oral dosage form of 
nateglinide instead of immediate release tablet.  
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